|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
US7435871B2
(en)
|
2001-11-30 |
2008-10-14 |
Amgen Fremont Inc. |
Transgenic animals bearing human Igλ light chain genes
|
|
AU2003222568B2
(en)
|
2002-01-11 |
2009-05-07 |
Bioasis Technologies, Inc. |
Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
EP1474522B1
(en)
*
|
2002-01-18 |
2012-03-07 |
Morphotek, Inc. |
A method for generating engineered cells for locus specific gene regulation and analysis
|
|
CN105884893A
(zh)
|
2002-07-18 |
2016-08-24 |
莫鲁斯有限公司 |
抗体混合物的重组生产
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
|
EP2395017A3
(en)
|
2003-05-30 |
2012-12-19 |
Merus B.V. |
Design and use of paired variable regions of specific binding molecules
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
GB2408980B
(en)
*
|
2003-12-09 |
2006-06-07 |
Nat Biolog Standards Board |
Genetic reference materials
|
|
ES2440990T5
(es)
|
2004-07-22 |
2022-10-25 |
Univ Erasmus Med Ct Rotterdam |
Moléculas de unión
|
|
EP2003960B1
(en)
*
|
2006-03-31 |
2015-06-10 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
|
CN101454345B
(zh)
*
|
2006-06-02 |
2012-08-08 |
瑞泽恩制药公司 |
人il-6受体的高亲和力抗体
|
|
WO2007147167A2
(en)
*
|
2006-06-16 |
2007-12-21 |
Porous Power Technologies, Llc |
Optimized microporous structure of electrochemical cells
|
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
DK2769992T3
(da)
|
2006-10-02 |
2021-03-22 |
Regeneron Pharma |
Humane antistoffer med høj affinitet for human IL-4-receptor
|
|
NO347649B1
(no)
|
2006-12-14 |
2024-02-12 |
Regeneron Pharma |
Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
|
|
JP5721951B2
(ja)
|
2007-03-22 |
2015-05-20 |
バイオジェン アイデック マサチューセッツ インコーポレイテッド |
抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用
|
|
SI2602323T1
(en)
*
|
2007-06-01 |
2018-05-31 |
Open Monoclonal Technology, Inc. |
Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
|
|
US9693539B2
(en)
*
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
|
MY153781A
(en)
|
2007-08-10 |
2015-03-13 |
Regeneron Pharma |
High affinity human antibodies to human nerve growth factor
|
|
GB0718029D0
(en)
*
|
2007-09-14 |
2007-10-24 |
Iti Scotland Ltd |
Two step cluster deletion and humanisation
|
|
PH12021552811A1
(en)
|
2007-09-26 |
2022-11-21 |
Chugai Pharmaceutical Co Ltd |
Modified antibody constant region
|
|
US20110119779A1
(en)
*
|
2007-12-10 |
2011-05-19 |
Aliva Biopharmaceuticals, Inc. |
Methods for sequential replacement of targeted region by homologous recombination
|
|
WO2009103082A2
(en)
*
|
2008-02-17 |
2009-08-20 |
Porous Power Technologies, Llc |
Lamination configurations for battery applications using pvdf highly porous film
|
|
US20090222995A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Bedding Applications for Porous Material
|
|
US20090226683A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Porous Material Uses in Furniture
|
|
US20090227163A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Protective Apparel with Porous Material Layer
|
|
US20090223155A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Bernard Perry |
Building Construction Applications for Porous Material
|
|
EP2098536A1
(en)
|
2008-03-05 |
2009-09-09 |
4-Antibody AG |
Isolation and identification of antigen- or ligand-specific binding proteins
|
|
MX348362B
(es)
*
|
2008-03-31 |
2017-06-07 |
Genentech Inc * |
Composiciones y metodos para tratar y diagnosticar asma.
|
|
EP2288623B1
(en)
*
|
2008-05-23 |
2013-07-10 |
Ablexis, LLC |
Method of generating single vl domain antibodies in transgenic animals
|
|
US20100122358A1
(en)
*
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
AU2014203150C1
(en)
*
|
2008-06-27 |
2018-10-18 |
Merus N.V. |
Antibody producing non-human mammals
|
|
DK2556747T3
(da)
*
|
2008-06-27 |
2021-02-15 |
Merus Nv |
Antistofproducerende transgen mus
|
|
DK2346994T3
(da)
|
2008-09-30 |
2022-02-28 |
Ablexis Llc |
Knock-in-mus til fremstilling af kimære antistoffer
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
RU2011129459A
(ru)
|
2008-12-18 |
2013-01-27 |
Эрасмус Юниверсити Медикал Сентр Роттердам |
Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение
|
|
US20100178567A1
(en)
*
|
2008-12-24 |
2010-07-15 |
Porous Power Technologies, Llc |
Mat Forming Spacers in Microporous Membrane Matrix
|
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗－α５β１抗體及其用途
|
|
JP2012527738A
(ja)
*
|
2009-05-20 |
2012-11-08 |
ポーラス パワー テクノロジーズ，エルエルシー |
微多孔膜の処理と接着剤
|
|
TWI513465B
(zh)
|
2009-06-25 |
2015-12-21 |
Regeneron Pharma |
以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
|
|
KR101962476B1
(ko)
|
2009-07-03 |
2019-03-26 |
아비펩 피티와이 리미티트 |
면역성 접합체 및 그 제조방법
|
|
EP2517556B2
(en)
*
|
2009-07-08 |
2023-03-22 |
Kymab Limited |
Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
|
|
US9445581B2
(en)
*
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3417701T3
(da)
*
|
2009-10-06 |
2022-03-14 |
Regeneron Pharma |
Genmodificerede mus og indpodning
|
|
DK2509409T3
(en)
*
|
2009-12-10 |
2016-11-14 |
Regeneron Pharma |
MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
|
|
WO2011072266A2
(en)
|
2009-12-11 |
2011-06-16 |
Atyr Pharma, Inc. |
Aminoacyl trna synthetases for modulating hematopoiesis
|
|
EP3336102A3
(en)
|
2009-12-21 |
2018-08-01 |
Regeneron Pharmaceuticals, Inc. |
Humanized fc gamma r mice
|
|
CA2784610C
(en)
|
2009-12-23 |
2020-07-14 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
|
US20120021409A1
(en)
*
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
US20130045492A1
(en)
*
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
WO2011097603A1
(en)
*
|
2010-02-08 |
2011-08-11 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
US20130185821A1
(en)
*
|
2010-02-08 |
2013-07-18 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
|
BR112012017405A2
(pt)
|
2010-02-18 |
2018-08-14 |
Genentech Inc |
método para aumentar o tempo até a recorrência do tumor em paciente com câncer
|
|
CN102906117B
(zh)
|
2010-03-24 |
2016-04-06 |
霍夫曼-拉罗奇有限公司 |
抗lrp6抗体
|
|
KR102004106B1
(ko)
|
2010-03-31 |
2019-07-25 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
|
EP2563380B1
(en)
|
2010-04-26 |
2018-05-30 |
aTyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
|
|
AU2011248614B2
(en)
|
2010-04-27 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases
|
|
WO2011139853A2
(en)
|
2010-04-28 |
2011-11-10 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
|
|
AU2011248457B2
(en)
|
2010-04-29 |
2017-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
|
|
CA2797374C
(en)
|
2010-04-29 |
2021-02-16 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
|
|
CN103096912A
(zh)
|
2010-05-03 |
2013-05-08 |
Atyr医药公司 |
与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
|
|
AU2011248230B2
(en)
|
2010-05-03 |
2016-10-06 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
|
|
US8961961B2
(en)
|
2010-05-03 |
2015-02-24 |
a Tyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
|
|
US9062302B2
(en)
|
2010-05-04 |
2015-06-23 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
|
|
AU2011252990B2
(en)
|
2010-05-14 |
2017-04-20 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-tRNA synthetases
|
|
CA2800375C
(en)
|
2010-05-27 |
2021-03-09 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
|
|
CN102933074B
(zh)
|
2010-06-11 |
2015-04-08 |
瑞泽恩制药公司 |
由xy es细胞制备能育的xy雌性动物
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
SG186238A1
(en)
|
2010-06-17 |
2013-01-30 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
EP2582729A4
(en)
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
|
SMT201900241T1
(it)
|
2010-06-22 |
2019-05-10 |
Regeneron Pharma |
Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
|
|
CA2803792A1
(en)
|
2010-07-09 |
2012-01-12 |
Genentech, Inc. |
Anti-neuropilin antibodies and methods of use
|
|
WO2012021247A2
(en)
|
2010-07-12 |
2012-02-16 |
Atyr Pharma, Inc. |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
|
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
DK2597945T3
(da)
*
|
2010-07-26 |
2020-09-21 |
Trianni Inc |
Transgene dyr og fremgangsmåder til anvendelse deraf
|
|
RS55495B1
(sr)
|
2010-08-02 |
2017-04-28 |
Regeneron Pharma |
Miševi koji stvaraju vezujuće proteine koji sadrže vl domene
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
BR112013002532A2
(pt)
|
2010-08-05 |
2016-05-31 |
Hoffmann La Roche |
proteína de fusão de citocina anti-viral do anticorpo anti-mhc
|
|
MX2013001267A
(es)
|
2010-08-13 |
2013-04-10 |
Genentech Inc |
ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD.
|
|
NZ703653A
(en)
|
2010-08-13 |
2016-09-30 |
Roche Glycart Ag |
Anti-fap antibodies and methods of use
|
|
BR112013002444A2
(pt)
|
2010-08-13 |
2016-05-24 |
Roche Glycart Ag |
anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
|
|
AU2011293294B2
(en)
|
2010-08-25 |
2016-03-24 |
Pangu Biopharma Limited |
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
|
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
|
US20130224116A1
(en)
|
2010-11-05 |
2013-08-29 |
TransBio Ltd. |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
|
WO2012064836A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
|
US8771696B2
(en)
|
2010-11-23 |
2014-07-08 |
Regeneron Pharmaceuticals, Inc. |
Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
|
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
|
TWI666447B
(zh)
|
2010-12-16 |
2019-07-21 |
建南德克公司 |
關於ｔｈ２抑制作用之診斷及治療
|
|
TWI589589B
(zh)
|
2010-12-20 |
2017-07-01 |
建南德克公司 |
抗間皮素（ｍｅｓｏｔｈｅｌｉｎ）抗體及免疫接合物
|
|
MX2013007168A
(es)
|
2010-12-22 |
2013-11-04 |
Genentech Inc |
Anticuerpo anti-pcsk9 y metodos de uso.
|
|
RU2013135175A
(ru)
|
2011-01-03 |
2015-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Фармацевтическая композиция комплекса антитела против дигоксигенина и дигоксигенина, конъюгированного с пептидом
|
|
DK2663579T3
(en)
|
2011-01-14 |
2017-07-31 |
Univ California |
THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF
|
|
WO2012101252A2
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
CN107474133B
(zh)
|
2011-02-08 |
2021-10-15 |
米迪缪尼有限公司 |
特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
|
|
MX338971B
(es)
|
2011-02-15 |
2016-05-06 |
Inst Res Biomedicine Irb |
Ratones de m-csf humanizada.
|
|
HRP20230526T1
(hr)
|
2011-02-25 |
2023-09-01 |
Regeneron Pharmaceuticals, Inc. |
Adam6 miševi
|
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
|
ES2692268T5
(en)
|
2011-03-29 |
2025-02-26 |
Roche Glycart Ag |
Antibody fc variants
|
|
TW201249867A
(en)
|
2011-04-01 |
2012-12-16 |
Astellas Pharma Inc |
Novel anti-human il-23 receptor antibody
|
|
WO2012138975A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
|
CN103619877B
(zh)
|
2011-04-21 |
2018-01-02 |
加文医学研究所 |
修饰的可变结构域分子及其产生和使用方法b
|
|
AR088782A1
(es)
|
2011-04-29 |
2014-07-10 |
Sanofi Sa |
Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes
|
|
EP2631654B1
(en)
|
2011-05-12 |
2015-04-15 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
|
EP2707723B1
(en)
|
2011-05-12 |
2016-02-10 |
Genentech, Inc. |
Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides
|
|
MY175338A
(en)
|
2011-05-16 |
2020-06-19 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
JP6187777B2
(ja)
|
2011-06-13 |
2017-08-30 |
シーエスエル、リミテッド |
Ｇ−ｃｓｆｒに対する抗体およびその使用
|
|
CN103596984B
(zh)
|
2011-06-15 |
2016-04-13 |
霍夫曼-拉罗奇有限公司 |
抗-人epo受体的抗体及使用方法
|
|
JP2014522843A
(ja)
|
2011-06-30 |
2014-09-08 |
ジェネンテック， インコーポレイテッド |
抗ｃ−ｍｅｔ抗体製剤
|
|
EP2739300B1
(en)
|
2011-07-05 |
2019-06-19 |
Duke University |
N-terminal deleted gp120 immunogens
|
|
EP2717917B1
(en)
|
2011-07-05 |
2016-04-20 |
biOasis Technologies Inc |
P97-antibody conjugates
|
|
WO2013015821A1
(en)
|
2011-07-22 |
2013-01-31 |
The Research Foundation Of State University Of New York |
Antibodies to the b12-transcobalamin receptor
|
|
US9120858B2
(en)
|
2011-07-22 |
2015-09-01 |
The Research Foundation Of State University Of New York |
Antibodies to the B12-transcobalamin receptor
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
SI3865581T1
(sl)
|
2011-08-05 |
2024-12-31 |
Regeneron Pharmaceuticals, Inc. |
Miši s humanizirano univerzalno lahko verigo
|
|
EP3321281B1
(en)
|
2011-08-05 |
2019-11-27 |
biOasis Technologies Inc |
P97 fragments with transfer activity
|
|
SMT201800166T1
(it)
|
2011-08-11 |
2018-05-02 |
Astellas Pharma Inc |
Nuovo anticorpo anti-ngf umano
|
|
KR20140057326A
(ko)
|
2011-08-17 |
2014-05-12 |
제넨테크, 인크. |
뉴레귤린 항체 및 그의 용도
|
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
|
MX359833B
(es)
|
2011-08-19 |
2018-10-12 |
Regeneron Pharma |
Anticuerpos anti-tie2 y usos de los mismos.
|
|
US20130058936A1
(en)
|
2011-08-23 |
2013-03-07 |
Peter Bruenker |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
RU2617970C2
(ru)
|
2011-08-23 |
2017-04-28 |
Рош Гликарт Аг |
Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
|
|
MX2014002053A
(es)
|
2011-08-23 |
2014-04-25 |
Roche Glycart Ag |
Anticuerpos anti -mcsp y metodos de uso.
|
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
|
EP2756004B1
(en)
|
2011-09-16 |
2019-12-25 |
Regeneron Pharmaceuticals, Inc. |
INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9) FOR USE IN REDUCING LIPOPROTEIN(a) LEVELS
|
|
MX2014002990A
(es)
|
2011-09-19 |
2014-05-21 |
Genentech Inc |
Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
|
|
CA2846319A1
(en)
|
2011-09-19 |
2013-03-28 |
Kymab Limited |
Antibodies, variable domains & chains tailored for human use
|
|
JP2014531452A
(ja)
|
2011-09-19 |
2014-11-27 |
カイマブ・リミテッド |
動物、レパートリーおよび方法
|
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
|
EP2761008A1
(en)
|
2011-09-26 |
2014-08-06 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
CA2850745C
(en)
|
2011-10-03 |
2022-12-13 |
Duke University |
Vaccine
|
|
US20130089562A1
(en)
|
2011-10-05 |
2013-04-11 |
Genenthech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
|
EP2766393B1
(en)
|
2011-10-14 |
2018-07-18 |
F.Hoffmann-La Roche Ag |
ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
|
|
CA2850836A1
(en)
|
2011-10-15 |
2013-04-18 |
Genentech, Inc. |
Methods of using scd1 antagonists
|
|
SG10202010120XA
(en)
*
|
2011-10-17 |
2020-11-27 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
WO2013063391A2
(en)
|
2011-10-28 |
2013-05-02 |
Trianni, Inc. |
Transgenic animals and methods of use
|
|
LT3590332T
(lt)
|
2011-10-28 |
2022-08-10 |
Regeneron Pharmaceuticals, Inc. |
Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
|
|
EP2771351B1
(en)
|
2011-10-28 |
2017-06-14 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
|
WO2013063001A1
(en)
|
2011-10-28 |
2013-05-02 |
Genentech, Inc. |
Therapeutic combinations and methods of treating melanoma
|
|
IN2014CN03890A
(cg-RX-API-DMAC7.html)
*
|
2011-10-28 |
2015-10-16 |
Regeneron Pharma |
|
|
LT3262932T
(lt)
|
2011-10-28 |
2019-08-26 |
Regeneron Pharmaceuticals, Inc. |
Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
|
|
GB2496375A
(en)
*
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
CN104066748A
(zh)
|
2011-11-21 |
2014-09-24 |
霍夫曼-拉罗奇有限公司 |
抗c-met抗体的纯化
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
US9253965B2
(en)
*
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP2788024A1
(en)
|
2011-12-06 |
2014-10-15 |
F.Hoffmann-La Roche Ag |
Antibody formulation
|
|
PL2793567T3
(pl)
*
|
2011-12-20 |
2019-09-30 |
Regeneron Pharmaceuticals, Inc. |
Myszy z humanizowanym łańcuchem lekkim
|
|
MX355625B
(es)
|
2011-12-22 |
2018-04-25 |
Hoffmann La Roche |
Organizacion de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
|
|
JP2015503907A
(ja)
|
2011-12-22 |
2015-02-05 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
真核細胞のための全長抗体提示システムおよびその使用
|
|
KR20140107507A
(ko)
*
|
2011-12-22 |
2014-09-04 |
아스텔라스세이야쿠 가부시키가이샤 |
신규 항 인간 ctgf 항체
|
|
RU2756910C2
(ru)
|
2011-12-22 |
2021-10-06 |
Ф. Хоффманн-Ля Рош Аг |
Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
|
|
WO2013096791A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Process for making high concentration protein formulations
|
|
RU2014133547A
(ru)
|
2012-01-18 |
2016-03-10 |
Дженентек, Инк. |
Способы применения модуляторов fgf19
|
|
SG10201601747XA
(en)
|
2012-01-18 |
2016-04-28 |
Genentech Inc |
Anti-LRP5 Antibodies And Methods Of Use
|
|
PL3597038T3
(pl)
|
2012-02-01 |
2021-11-08 |
Regeneron Pharmaceuticals, Inc. |
Humanizowane gryzonie wykazujące ekspresję łańcuchów ciężkich zawierających domeny vl
|
|
MX366804B
(es)
|
2012-02-11 |
2019-07-25 |
Genentech Inc |
Translocaciones de la r-espondina y sus metodos de uso.
|
|
CN104125852B9
(zh)
|
2012-02-15 |
2017-05-17 |
弗·哈夫曼-拉罗切有限公司 |
基于Fc‑受体的亲和色谱
|
|
MX356107B
(es)
|
2012-02-16 |
2018-05-15 |
Atyr Pharma Inc |
Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias.
|
|
JP6137169B2
(ja)
|
2012-02-28 |
2017-05-31 |
アステラス製薬株式会社 |
新規抗ヒトｉｌ−２３受容体抗体
|
|
AR090219A1
(es)
|
2012-03-02 |
2014-10-29 |
Regeneron Pharma |
Anticuerpos humanos frente a toxinas de clostridium difficile
|
|
AU2013204140B2
(en)
|
2012-03-06 |
2016-01-28 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
HRP20191248T1
(hr)
|
2012-03-13 |
2019-10-18 |
F. Hoffmann - La Roche Ag |
Kombinirana terapija za liječenje karcinoma jajnika
|
|
RU2644684C2
(ru)
|
2012-03-16 |
2018-02-13 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
|
AU2013204581B2
(en)
|
2012-03-16 |
2015-06-25 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing pH-sensitive immunoglobulin sequences
|
|
HUE045537T2
(hu)
|
2012-03-16 |
2019-12-30 |
Regeneron Pharma |
PH-érzékeny immunglobulin-szekvenciákat expresszáló rágcsálók
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
JP2015514710A
(ja)
|
2012-03-27 |
2015-05-21 |
ジェネンテック， インコーポレイテッド |
Ｈｅｒ３阻害剤に関する診断及び治療
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
JP2015512635A
(ja)
|
2012-03-28 |
2015-04-30 |
カイマブ・リミテッド |
クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
|
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗－ｈｌａ－ｂ*２７抗體及其用途
|
|
MX360110B
(es)
|
2012-04-20 |
2018-10-23 |
Merus Nv |
Metodos y medios para la produccion de moleculas de tipo ig.
|
|
PT2847335T
(pt)
|
2012-04-25 |
2018-09-28 |
Regeneron Pharma |
Alvejamento mediado por nuclease com vetores de alvejamento grandes
|
|
EP2844300B1
(en)
|
2012-05-01 |
2018-10-17 |
Genentech, Inc. |
Anti-pmel17 antibodies and immunoconjugates
|
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
|
KR101843614B1
(ko)
|
2012-05-23 |
2018-03-29 |
제넨테크, 인크. |
치료제의 선택 방법
|
|
AR092325A1
(es)
|
2012-05-31 |
2015-04-15 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
|
|
KR20150023535A
(ko)
*
|
2012-06-05 |
2015-03-05 |
리제너론 파마슈티칼스 인코포레이티드 |
공통 경쇄를 사용하여 완전한 인간 이중 특이적 항체를 만드는 방법
|
|
CN104540383B
(zh)
*
|
2012-06-12 |
2017-08-29 |
瑞泽恩制药公司 |
具有受限制的免疫球蛋白重链基因座的人源化非人动物
|
|
CA2875096A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
ES2604012T3
(es)
|
2012-07-04 |
2017-03-02 |
F. Hoffmann-La Roche Ag |
Conjugados de antígeno-anticuerpo unidos covalentemente
|
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
|
WO2014006118A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-theophylline antibodies and methods of use
|
|
EP3578660A1
(en)
|
2012-07-05 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Expression and secretion system
|
|
AU2013288929A1
(en)
|
2012-07-09 |
2014-12-04 |
Genentech, Inc. |
Immunoconjugates comprising anti-CD22 antibodies
|
|
MX2015000314A
(es)
|
2012-07-09 |
2015-04-10 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados.
|
|
KR20150030754A
(ko)
|
2012-07-09 |
2015-03-20 |
제넨테크, 인크. |
항-cd22 항체를 포함하는 면역접합체
|
|
CN104540526A
(zh)
|
2012-07-09 |
2015-04-22 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
|
PT2872157T
(pt)
|
2012-07-12 |
2020-04-30 |
Hangzhou Dac Biotech Co Ltd |
Conjugados de moléculas de ligação celular com agentes citotóxicos
|
|
RS57704B1
(sr)
|
2012-07-13 |
2018-12-31 |
Roche Glycart Ag |
Bispecifična anti-vegf/anti-ang-2 antitela i njihova primena u lečenju vaskularnih bolesti oka
|
|
WO2014018375A1
(en)
|
2012-07-23 |
2014-01-30 |
Xenon Pharmaceuticals Inc. |
Cyp8b1 and uses thereof in therapeutic and diagnostic methods
|
|
AU2013296557B2
(en)
|
2012-07-31 |
2019-04-18 |
Bioasis Technologies Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
CN104507498A
(zh)
|
2012-08-07 |
2015-04-08 |
霍夫曼-拉罗奇有限公司 |
用于治疗成胶质细胞瘤的组合疗法
|
|
CN104755495A
(zh)
|
2012-08-21 |
2015-07-01 |
赛诺菲 |
通过施用il-4r拮抗剂治疗或预防哮喘的方法
|
|
KR102274722B1
(ko)
|
2012-08-23 |
2021-07-09 |
어젠시스 인코포레이티드 |
158p1d7 단백질에 결합하는 항체
|
|
ES2992753T3
(en)
|
2012-08-24 |
2024-12-17 |
Univ California |
Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2703008A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
CN120718856A
(zh)
|
2012-09-07 |
2025-09-30 |
再生元制药公司 |
经遗传修饰的非人动物及其使用方法
|
|
RU2698907C2
(ru)
|
2012-09-07 |
2019-09-02 |
Ридженерон Фармасьютикалз, Инк. |
Способы лечения атопического дерматита с помощью антагониста il-4r
|
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
|
|
EP2906681B1
(en)
*
|
2012-10-12 |
2019-01-09 |
GlaxoSmithKline Biologicals S.A. |
Methods of host cell modification
|
|
CA2890346A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel fusion molecules and uses thereof
|
|
ES2748662T3
(es)
|
2012-11-05 |
2020-03-17 |
Institute For Res In Biomedicine Irb |
Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
|
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
|
EP3640338A1
(en)
|
2012-11-06 |
2020-04-22 |
Medlmmune, LLC |
Antibodies to s. aureus surface determinants
|
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
|
SG11201503734UA
(en)
|
2012-11-13 |
2015-06-29 |
Genentech Inc |
Anti-hemagglutinin antibodies and methods of use
|
|
AR093445A1
(es)
|
2012-11-14 |
2015-06-10 |
Regeneron Pharma |
Metodos para tratar el cancer de ovario con antagonistas de dll4
|
|
EP2922818B1
(en)
|
2012-11-24 |
2018-09-05 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
ES2963516T3
(es)
|
2012-12-14 |
2024-03-27 |
Omniab Inc |
Polinucleótidos que codifican anticuerpos de roedores con idiotipos humanos y animales que los contienen
|
|
WO2014107739A1
(en)
|
2013-01-07 |
2014-07-10 |
Eleven Biotherapeutics, Inc. |
Antibodies against pcsk9
|
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
|
HK1218866A1
(zh)
|
2013-02-06 |
2017-03-17 |
瑞泽恩制药公司 |
基於b细胞谱系的人源化动物的免疫原设计
|
|
PL2953971T3
(pl)
|
2013-02-07 |
2023-07-03 |
Csl Limited |
Białka wiążące il-11r i ich zastosowania
|
|
SMT201900429T1
(it)
|
2013-02-20 |
2019-09-09 |
Regeneron Pharma |
Topi esprimenti co-recettori umanizzati linfociti t
|
|
WO2014130690A1
(en)
*
|
2013-02-20 |
2014-08-28 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
EP3561050B1
(en)
|
2013-02-20 |
2021-12-08 |
Regeneron Pharmaceuticals, Inc. |
Genetic modification of rats
|
|
EP2958937B1
(en)
*
|
2013-02-22 |
2018-08-15 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing humanized major histocompatibility complex
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
WO2014128235A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
|
US20140242083A1
(en)
|
2013-02-26 |
2014-08-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
|
CN105246511A
(zh)
|
2013-03-06 |
2016-01-13 |
豪夫迈·罗氏有限公司 |
治疗和预防癌症药物抗性的方法
|
|
JP6456350B2
(ja)
*
|
2013-03-11 |
2019-01-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
|
|
EP4545567A3
(en)
*
|
2013-03-13 |
2025-08-13 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
WO2014160438A1
(en)
|
2013-03-13 |
2014-10-02 |
Bioasis Technologies Inc. |
Fragments of p97 and uses thereof
|
|
CA2903696A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
|
PE20151672A1
(es)
|
2013-03-14 |
2015-11-27 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4
|
|
US9980470B2
(en)
|
2013-03-14 |
2018-05-29 |
Erasmus University Medical Center |
Antibody production
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
KR20150129718A
(ko)
|
2013-03-14 |
2015-11-20 |
리제너론 파아마슈티컬스, 인크. |
Ｇｒｅｍ 1에 대한 인간 항체
|
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
|
US20140271634A1
(en)
|
2013-03-14 |
2014-09-18 |
The Regents Of The University Of California |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
|
MY197809A
(en)
|
2013-03-15 |
2023-07-18 |
Genentech Inc |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
|
KR20150131177A
(ko)
|
2013-03-15 |
2015-11-24 |
제넨테크, 인크. |
항-CRTh2 항체 및 그의 용도
|
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
|
MY183572A
(en)
|
2013-03-15 |
2021-02-26 |
Regeneron Pharma |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
CN105143264A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
用于肝癌诊断和治疗的组合物和方法
|
|
WO2014144292A2
(en)
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
CN105143258B
(zh)
|
2013-03-15 |
2020-06-23 |
Ac免疫有限公司 |
抗Tau抗体和使用方法
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
HUE040575T2
(hu)
*
|
2013-04-16 |
2019-03-28 |
Regeneron Pharma |
A patkány genom célzott módosítása
|
|
JP6618893B2
(ja)
|
2013-04-29 |
2019-12-11 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｆｃ受容体結合が変更された非対称抗体および使用方法
|
|
KR102282134B1
(ko)
|
2013-04-29 |
2021-07-27 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
US11707056B2
(en)
*
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US20140331339A1
(en)
*
|
2013-05-03 |
2014-11-06 |
Kymab Limited |
Transgenic Non-Human Assay Vertebrates, Assays and Kits
|
|
AU2014268726B2
(en)
|
2013-05-20 |
2019-10-31 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
|
TWI682780B
(zh)
|
2013-05-30 |
2020-01-21 |
美商再生元醫藥公司 |
醫藥組成物用於製造治療與ｐｃｓｋ９功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途
|
|
EP2810955A1
(en)
|
2013-06-07 |
2014-12-10 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
EA201592267A1
(ru)
|
2013-06-07 |
2016-04-29 |
Ридженерон Фармасьютикалз, Инк. |
Способы ингибирования атеросклероза посредством введения ингибитора pcsk9
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
PL3010539T3
(pl)
|
2013-06-21 |
2020-01-31 |
Sanofi Biotechnology |
Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
|
|
TWI646108B
(zh)
|
2013-08-01 |
2019-01-01 |
艾澤西公司 |
結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
|
|
KR102138723B1
(ko)
|
2013-08-07 |
2020-07-29 |
리제너론 파마슈티칼스 인코포레이티드 |
Lincrna-결핍 비인간 동물
|
|
ES2730978T3
(es)
|
2013-08-09 |
2019-11-13 |
Astellas Pharma Inc |
Anticuerpo anti-receptor de TSLP humana nuevo
|
|
EP3036543B1
(en)
|
2013-08-23 |
2019-06-19 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
|
CN105530942B
(zh)
|
2013-08-26 |
2019-10-11 |
瑞泽恩制药公司 |
一种包含大环内酯类非对映体的药物组合物、其制备方法和用途
|
|
AU2014312190A1
(en)
|
2013-08-28 |
2016-02-18 |
Bioasis Technologies Inc. |
CNS-targeted conjugates of antibodies
|
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
|
WO2015028850A1
(en)
|
2013-09-02 |
2015-03-05 |
Hangzhou Dac Biotech Co., Ltd |
Novel cytotoxic agents for conjugation of drugs to cell binding molecule
|
|
HK1218124A1
(zh)
|
2013-09-17 |
2017-02-03 |
豪夫迈．罗氏有限公司 |
使用抗lgr5抗体的方法
|
|
DE202014010413U1
(de)
|
2013-09-18 |
2015-12-08 |
Kymab Limited |
Zellen und Organismen
|
|
LT3046412T
(lt)
*
|
2013-09-18 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
|
|
ES2993142T3
(en)
*
|
2013-10-01 |
2024-12-23 |
Kymab Ltd |
Animal models and therapeutic molecules
|
|
BR112016007635A2
(pt)
|
2013-10-11 |
2017-09-12 |
Genentech Inc |
inibidores de nsp4 e métodos de uso
|
|
EA037526B1
(ru)
|
2013-10-11 |
2021-04-08 |
Санофи Байотекнолоджи |
Применение ингибитора pcsk9 для лечения гиперлипидемии
|
|
CA2925598A1
(en)
|
2013-10-18 |
2015-04-23 |
Genentech, Inc. |
Anti-rspo antibodies and methods of use
|
|
BR112016008694A2
(pt)
|
2013-10-23 |
2017-10-03 |
Genentech Inc |
Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
|
|
SI3065774T1
(sl)
|
2013-11-06 |
2021-11-30 |
Janssen Biotech, Inc. |
Protitelesa proti CCL17
|
|
EA201690889A1
(ru)
|
2013-11-12 |
2016-11-30 |
Санофи Байотекнолоджи |
Режимы дозирования для применения ингибиторов pcsk9
|
|
CA2924268C
(en)
|
2013-11-21 |
2021-05-18 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
|
SMT201800653T1
(it)
|
2013-12-11 |
2019-01-11 |
Regeneron Pharma |
Metodi e composizioni per la modificazione indirizzata a bersaglio di un genoma
|
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
|
CN105934253A
(zh)
|
2013-12-17 |
2016-09-07 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
|
|
PT3083689T
(pt)
|
2013-12-17 |
2020-08-27 |
Genentech Inc |
Anticorpos anti-cd3 e métodos de utilização
|
|
JP2017501167A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック， インコーポレイテッド |
Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
|
|
SG11201604875PA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
EP3088519A4
(en)
|
2013-12-24 |
2017-09-13 |
Astellas Pharma Inc. |
Novel anti-human bdca-2 antibody
|
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
JP6602304B2
(ja)
|
2014-01-03 |
2019-11-06 |
エフ．ホフマン−ラ ロシュ アーゲー |
共有結合で連結されたヘリカー−抗ヘリカー抗体コンジュゲートおよびその用途
|
|
CA2933384A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
|
CN110903398B
(zh)
|
2014-01-15 |
2023-08-15 |
豪夫迈·罗氏有限公司 |
具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
WO2015112909A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
|
WO2015116852A1
(en)
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
|
US20160347821A1
(en)
|
2014-02-03 |
2016-12-01 |
Bioasis Technologies, Inc. |
P97 fusion proteins
|
|
ES2873248T3
(es)
|
2014-02-08 |
2021-11-03 |
Hoffmann La Roche |
Métodos para tratar la enfermedad de Alzheimer
|
|
US20150246963A1
(en)
|
2014-02-08 |
2015-09-03 |
Genentech, Inc. |
Methods of treating alzheimer's disease
|
|
JP6571115B2
(ja)
|
2014-02-12 |
2019-09-04 |
ジェネンテック， インコーポレイテッド |
抗ｊａｇｇｅｄ１抗体及び使用方法
|
|
CA2939507A1
(en)
|
2014-02-14 |
2015-08-20 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
|
|
WO2015126729A1
(en)
|
2014-02-19 |
2015-08-27 |
Bioasis Technologies, Inc. |
P97-ids fusion proteins
|
|
IL315136A
(en)
|
2014-02-21 |
2024-10-01 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-4rantagonist
|
|
CA2937556A1
(en)
|
2014-02-21 |
2015-08-27 |
Genentech, Inc. |
Anti-il-13/il-17 bispecific antibodies and uses thereof
|
|
WO2015127685A1
(en)
|
2014-02-28 |
2015-09-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
ES2897765T3
(es)
|
2014-03-14 |
2022-03-02 |
Hoffmann La Roche |
Procedimientos y composiciones para la secreción de polipéptidos heterólogos
|
|
CN106794244A
(zh)
|
2014-03-17 |
2017-05-31 |
赛诺菲生物技术公司 |
用于降低心血管风险的方法
|
|
WO2015143406A2
(en)
|
2014-03-21 |
2015-09-24 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
WO2015140591A1
(en)
|
2014-03-21 |
2015-09-24 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
|
CN106103478B
(zh)
|
2014-03-21 |
2020-04-03 |
豪夫迈·罗氏有限公司 |
抗体体内半寿期的体外预测
|
|
ES2872475T3
(es)
|
2014-03-21 |
2021-11-02 |
Regeneron Pharma |
Animales no humanos que producen proteínas de unión de dominio único
|
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
|
EP3126386A1
(en)
|
2014-03-31 |
2017-02-08 |
F. Hoffmann-La Roche AG |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
|
JP6637439B2
(ja)
|
2014-03-31 |
2020-01-29 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体及び使用方法
|
|
KR102376287B1
(ko)
|
2014-04-02 |
2022-03-17 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체 경쇄 잘못짝짓기의 검출 방법
|
|
CN106459213B
(zh)
|
2014-04-03 |
2020-12-01 |
Igm生物科学股份有限公司 |
修饰的j链
|
|
EP3131931B1
(en)
|
2014-04-18 |
2020-10-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating sickle-cell disease
|
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
|
EP3137610B1
(en)
|
2014-05-01 |
2019-03-06 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
|
NO2785538T3
(cg-RX-API-DMAC7.html)
|
2014-05-07 |
2018-08-04 |
|
|
|
EP4306648A3
(en)
|
2014-05-19 |
2024-04-17 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing human epo
|
|
KR20170003582A
(ko)
|
2014-05-22 |
2017-01-09 |
제넨테크, 인크. |
항-gpc3 항체 및 면역접합체
|
|
EP3146071B1
(en)
|
2014-05-23 |
2020-09-02 |
F. Hoffmann-La Roche AG |
Mit biomarkers and methods using the same
|
|
US9497945B2
(en)
*
|
2014-05-30 |
2016-11-22 |
Regeneron Pharmaceuticals, Inc. |
Humanized dipeptidyl peptidase IV (DPP4) animals
|
|
LT3152312T
(lt)
*
|
2014-06-06 |
2020-04-27 |
Regeneron Pharmaceuticals, Inc. |
Tikslinio lokuso modifikavimo būdai ir kompozicijos
|
|
EP3155015A1
(en)
|
2014-06-11 |
2017-04-19 |
F. Hoffmann-La Roche AG |
Anti-lgr5 antibodies and uses thereof
|
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
BR122023023170A2
(pt)
|
2014-06-13 |
2024-02-20 |
Acceleron Pharma Inc. |
Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia
|
|
JP6336140B2
(ja)
|
2014-06-23 |
2018-06-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
ヌクレアーゼ媒介ｄｎａアセンブリ
|
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
|
EP3461885B1
(en)
|
2014-06-26 |
2021-10-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for targeted genetic modifications and methods of use
|
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
|
CN107074925B
(zh)
|
2014-07-10 |
2021-08-24 |
阿费里斯股份公司 |
用于预防和/或治疗亨廷顿氏病的物质和方法
|
|
BR112017000130A2
(pt)
|
2014-07-11 |
2018-01-09 |
Genentech Inc |
método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
|
|
JP2017523776A
(ja)
|
2014-07-14 |
2017-08-24 |
ジェネンテック， インコーポレイテッド |
膠芽腫の診断方法及びその治療用組成物
|
|
PL3169353T3
(pl)
|
2014-07-16 |
2020-06-01 |
Sanofi Biotechnology |
SPOSOBY LECZENIA PACJENTÓW Z HETEROZYGOTYCZNĄ HIPERCHOLESTEROLEMIĄ RODZINNĄ (heFH)
|
|
AU2015289617B2
(en)
|
2014-07-16 |
2021-04-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating high cardiovascular risk patients with hypercholesterolemia
|
|
BR112017002629A2
(pt)
|
2014-08-15 |
2018-02-20 |
Adynxx, Inc. |
decoys de oligonucleotídeo para o tratamento de dor
|
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
|
CN106804108B
(zh)
|
2014-09-12 |
2021-08-10 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
SG11201701623UA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Anti-her2 antibodies and immunoconjugates
|
|
CA2960763A1
(en)
|
2014-09-16 |
2016-03-24 |
Regeneron Pharmaceuticals, Inc. |
Anti-glucagon antibodies and uses thereof
|
|
CA2957148A1
(en)
|
2014-09-17 |
2016-03-24 |
Genentech, Inc. |
Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
MX2017003841A
(es)
|
2014-09-23 |
2018-02-23 |
Regeneron Pharma |
Anticuerpos anti-il-25 y usos de los mismos.
|
|
EP3262071B8
(en)
|
2014-09-23 |
2022-05-18 |
F. Hoffmann-La Roche AG |
Method of using anti-cd79b immunoconjugates
|
|
JP2017536811A
(ja)
|
2014-10-15 |
2017-12-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
多能性細胞の樹立又は維持のための方法及び組成物
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
US10584175B2
(en)
|
2014-10-23 |
2020-03-10 |
La Trobe University |
FN14-binding proteins and uses thereof
|
|
EP3223865A4
(en)
|
2014-10-31 |
2018-10-03 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
|
WO2016073378A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
CN107073126A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和tigit抑制剂的组合疗法
|
|
EP3215528B1
(en)
|
2014-11-06 |
2019-08-07 |
F.Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
|
EP3842453A1
(en)
|
2014-11-06 |
2021-06-30 |
F. Hoffmann-La Roche AG |
Fc-region variants with modified fcrn- and protein a-binding properties
|
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
|
KR20170080604A
(ko)
|
2014-11-10 |
2017-07-10 |
제넨테크, 인크. |
항-인터류킨-33 항체 및 그것의 용도
|
|
WO2016077666A1
(en)
|
2014-11-14 |
2016-05-19 |
Regeneron Pharmaceuticals, Inc. |
Method for generating high affinity antibodies
|
|
US10160795B2
(en)
|
2014-11-14 |
2018-12-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to Ebola virus glycoprotein and their use
|
|
KR20230158131A
(ko)
|
2014-11-14 |
2023-11-17 |
사노피 바이오테크놀로지 |
Ｉｌ-4ｒ 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
|
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
EP3221362B1
(en)
|
2014-11-19 |
2019-07-24 |
F.Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2016081639A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
LT3221355T
(lt)
|
2014-11-20 |
2020-12-28 |
F. Hoffmann-La Roche Ag |
Kombinuotoji t ląsteles aktyvinančių bispecifinių antigeną surišančių molekulių cd3 bei folato receptoriaus 1 (folr1) ir pd-1 ašą surišančių antagonistų terapija
|
|
HUE044907T2
(hu)
|
2014-11-21 |
2019-11-28 |
Regeneron Pharma |
Módszerek és készítmények célzott genetikai módosításhoz, párosított mutató RNS-ek használatával
|
|
RS63410B1
(sr)
|
2014-11-24 |
2022-08-31 |
Regeneron Pharma |
Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
|
|
JP6554280B2
(ja)
*
|
2014-11-28 |
2019-07-31 |
株式会社デンソーテン |
データ処理装置、画像処理方法、及び、プログラム
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
LT3227336T
(lt)
|
2014-12-05 |
2019-09-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b antikūnai ir jų naudojimo būdai
|
|
CA2966365A1
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
|
TWI702229B
(zh)
|
2014-12-19 |
2020-08-21 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
|
NZ732895A
(en)
|
2014-12-19 |
2022-05-27 |
Regeneron Pharma |
Methods and compositions for targeted genetic modification through single-step multiple targeting
|
|
AR103161A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
|
|
WO2016094962A1
(en)
|
2014-12-19 |
2016-06-23 |
Monash University |
Il-21 antibodies
|
|
AR103162A1
(es)
|
2014-12-19 |
2017-04-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y métodos para su uso
|
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
EP3247723A1
(en)
|
2015-01-22 |
2017-11-29 |
Chugai Seiyaku Kabushiki Kaisha |
A combination of two or more anti-c5 antibodies and methods of use
|
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
|
TW202248212A
(zh)
|
2015-02-05 |
2022-12-16 |
日商中外製藥股份有限公司 |
包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
|
|
EP3256164B1
(en)
|
2015-02-09 |
2020-03-25 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex
|
|
CA2975899A1
(en)
|
2015-02-13 |
2016-08-18 |
Biommune Technologies Inc. |
Antibodies to l-type voltage gated channels and related methods
|
|
UA122331C2
(uk)
|
2015-03-09 |
2020-10-26 |
Едженсіс, Інк. |
Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3
|
|
HK1247287A1
(zh)
|
2015-03-16 |
2018-09-21 |
F. Hoffmann-La Roche Ag |
检测和定量il-13的方法和在诊断和治疗th2相关疾病中的用途
|
|
US10285387B2
(en)
|
2015-03-16 |
2019-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
|
JP2018508224A
(ja)
|
2015-03-19 |
2018-03-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
抗原を結合する軽鎖可変領域を選択する非ヒト動物
|
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
|
ES2789348T3
(es)
|
2015-03-20 |
2020-10-26 |
Us Health |
Anticuerpos neutralizantes para GP120 y sus usos
|
|
DK3273992T3
(da)
|
2015-03-23 |
2020-07-27 |
Jounce Therapeutics Inc |
Antistoffer mod ICOS
|
|
MX386328B
(es)
|
2015-03-27 |
2025-03-18 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
|
|
DK3280257T3
(da)
|
2015-04-06 |
2023-09-04 |
Regeneron Pharma |
Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
|
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
|
JP7055636B2
(ja)
|
2015-04-06 |
2022-04-18 |
アクセルロン ファーマ インコーポレイテッド |
ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
|
|
HK1249532A1
(zh)
|
2015-04-07 |
2018-11-02 |
F. Hoffmann-La Roche Ag |
具有激动剂活性的抗原结合复合体及使用方法
|
|
PT3280441T
(pt)
|
2015-04-07 |
2021-11-30 |
Alector Llc |
Anticorpos anti-sortilina e métodos para a sua utilização
|
|
PT3282835T
(pt)
|
2015-04-13 |
2023-07-25 |
Univ Yale |
Ratinhos knockin de sirpa-il15 humanizadas e métodos de utilização dos mesmos
|
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
|
HK1252158A1
(zh)
|
2015-05-01 |
2019-05-17 |
Genentech, Inc. |
掩蔽抗cd3抗体和使用方法
|
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
|
EP3936524A3
(en)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Compositions and methods of treating lupus nephritis
|
|
ES2835866T5
(es)
|
2015-05-12 |
2024-12-02 |
Hoffmann La Roche |
Procedimientos terapéuticos y de diagnóstico para el cáncer
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
US10787516B2
(en)
|
2015-05-18 |
2020-09-29 |
Agensys, Inc. |
Antibodies that bind to AXL proteins
|
|
JP6913030B2
(ja)
|
2015-05-18 |
2021-08-04 |
アジェンシス，インコーポレイテッド |
Ａｘｌタンパク質に結合する抗体
|
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
|
ES3009538T3
(en)
|
2015-05-29 |
2025-03-27 |
Regeneron Pharma |
Rodent cells having a disruption in a c9orf72 locus
|
|
EP3303632B2
(en)
|
2015-05-29 |
2023-05-10 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
|
JP2018516933A
(ja)
|
2015-06-02 |
2018-06-28 |
ジェネンテック， インコーポレイテッド |
抗ｉｌ−３４抗体を使用して神経学的疾患を治療するための組成物及び方法
|
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
|
JP6793134B2
(ja)
|
2015-06-05 |
2020-12-02 |
ジェネンテック， インコーポレイテッド |
抗ｔａｕ抗体及び使用方法
|
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
|
AU2016274585A1
(en)
|
2015-06-08 |
2017-12-14 |
Genentech, Inc. |
Methods of treating cancer using anti-OX40 antibodies
|
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
|
JP7376977B2
(ja)
|
2015-06-12 |
2023-11-09 |
アレクトル エルエルシー |
抗ｃｄ３３抗体及びその使用方法
|
|
WO2016205176A1
(en)
|
2015-06-15 |
2016-12-22 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体及び使用方法
|
|
EP3310814B1
(en)
|
2015-06-16 |
2023-08-02 |
F. Hoffmann-La Roche AG |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
|
KR102689256B1
(ko)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
|
ES3043088T3
(en)
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
WO2016207240A1
(en)
|
2015-06-24 |
2016-12-29 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
|
CA2991973C
(en)
|
2015-07-12 |
2021-12-07 |
Suzhou M-Conj Biotech Co., Ltd. |
Bridge linkers for conjugation of a cell-binding molecule
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3331550B1
(en)
|
2015-08-04 |
2022-11-02 |
Acceleron Pharma Inc. |
Composition for treating myeloproliferative disorders
|
|
MA45573A
(fr)
|
2015-08-05 |
2019-05-15 |
Janssen Biotech Inc |
Anticorps anti-cd154 et procédés d'utilisation correspondant
|
|
TW201713690A
(zh)
|
2015-08-07 |
2017-04-16 |
再生元醫藥公司 |
抗ａｎｇｐｔｌ８抗體及其用途
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
AU2016308111A1
(en)
|
2015-08-18 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
|
WO2017035252A1
(en)
|
2015-08-24 |
2017-03-02 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
|
MY203894A
(en)
|
2015-09-18 |
2024-07-23 |
Chugai Pharmaceutical Co Ltd |
Il-8-binding antibodies and uses thereof
|
|
JP6959912B2
(ja)
|
2015-09-23 |
2021-11-05 |
ジェネンテック， インコーポレイテッド |
抗ｖｅｇｆ抗体の最適化変異体
|
|
RU2757135C2
(ru)
|
2015-09-24 |
2021-10-11 |
АБВИТРО ЭлЭлСи |
Композиции антител к вич и способы их применения
|
|
SMT202500003T1
(it)
|
2015-09-25 |
2025-03-12 |
Hoffmann La Roche |
Anticorpi anti-tigit e procedimenti di utilizzo
|
|
WO2017059380A1
(en)
|
2015-09-30 |
2017-04-06 |
Igm Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
BR112018006360A2
(pt)
|
2015-09-30 |
2018-10-09 |
Janssen Biotech Inc |
anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
|
|
JP7058213B2
(ja)
|
2015-09-30 |
2022-04-21 |
アイジーエム バイオサイエンシズ インコーポレイテッド |
改変ｊ鎖を有する結合分子
|
|
DK3356404T3
(da)
|
2015-10-02 |
2021-10-25 |
Hoffmann La Roche |
Anti-pd1-antistoffer og fremgangsmåder til anvendelse
|
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN114057884A
(zh)
|
2015-10-02 |
2022-02-18 |
豪夫迈·罗氏有限公司 |
双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
|
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗ｌａｇ３抗體及其用途
|
|
TWI752920B
(zh)
|
2015-10-12 |
2022-01-21 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
|
CA3088612C
(en)
|
2015-10-30 |
2022-04-12 |
Genentech, Inc. |
Anti-htra1 antibodies and methods of use thereof
|
|
EP3368074A2
(en)
|
2015-10-30 |
2018-09-05 |
Hoffmann-La Roche AG |
Anti-factor d antibodies and conjugates
|
|
PT3370768T
(pt)
|
2015-11-03 |
2022-04-21 |
Janssen Biotech Inc |
Anticorpos que se ligam especificamente ao pd-1 e seus usos
|
|
EP3370754A4
(en)
|
2015-11-04 |
2019-10-23 |
Acceleron Pharma Inc. |
METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE
|
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
|
WO2017091706A1
(en)
|
2015-11-23 |
2017-06-01 |
Acceleron Pharma Inc. |
Methods for treating eye disorders
|
|
HK1253533A1
(zh)
|
2015-11-27 |
2019-06-21 |
Csl Limited |
Cd131结合蛋白及其应用
|
|
US10813346B2
(en)
|
2015-12-03 |
2020-10-27 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
|
WO2017106684A2
(en)
|
2015-12-17 |
2017-06-22 |
Janssen Biotech, Inc. |
Antibodies specifically binding hla-dr and their uses
|
|
RU2742606C2
(ru)
|
2015-12-18 |
2021-02-09 |
Чугаи Сейяку Кабусики Кайся |
Антитела к с5 и способы их применения
|
|
AU2016372934B2
(en)
|
2015-12-18 |
2023-10-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
|
|
JP7126941B2
(ja)
|
2015-12-22 |
2022-08-29 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
|
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
|
KR102482103B1
(ko)
|
2016-01-13 |
2022-12-28 |
리제너론 파마슈티칼스 인코포레이티드 |
조작된 중쇄 다양성 영역을 갖는 설치류
|
|
EP3405489A1
(en)
|
2016-01-20 |
2018-11-28 |
Genentech, Inc. |
High dose treatments for alzheimer's disease
|
|
MX390630B
(es)
|
2016-01-25 |
2025-03-21 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
|
|
US11053288B2
(en)
|
2016-02-04 |
2021-07-06 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
JP6765433B2
(ja)
|
2016-02-12 |
2020-10-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
異常な核型の検出のための方法
|
|
AU2017221425A1
(en)
*
|
2016-02-16 |
2018-08-23 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a mutant kynureninase gene
|
|
IL260931B2
(en)
|
2016-02-17 |
2024-09-01 |
Regeneron Pharma |
Methods of treating or preventing atherosclerosis by blocking ANGPTL3
|
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
|
WO2017151783A1
(en)
|
2016-03-03 |
2017-09-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
|
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用ｐｄ－１軸結合拮抗劑和抗ｇｐｃ３抗體治療癌症的方法
|
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
|
EP3437001A1
(en)
|
2016-03-29 |
2019-02-06 |
Regeneron Pharmaceuticals, Inc. |
Genetic variant-phenotype analysis system and methods of use
|
|
IL299000A
(en)
*
|
2016-04-04 |
2023-02-01 |
Eth Zuerich |
A mammalian cell line for protein production and a breeding library
|
|
EP3439741A4
(en)
|
2016-04-06 |
2020-05-06 |
Acceleron Pharma Inc. |
ALK7 ANTAGONISTS AND USES THEREOF
|
|
EP3228630A1
(en)
|
2016-04-07 |
2017-10-11 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
|
|
CN109789194B
(zh)
|
2016-04-08 |
2022-08-02 |
瑞泽恩制药公司 |
用angptl8抑制剂和angptl3抑制剂治疗高脂血症的方法
|
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
JP7503887B2
(ja)
|
2016-04-15 |
2024-06-21 |
ジェネンテック， インコーポレイテッド |
がんを監視及び治療するための方法
|
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
|
AU2017258105B2
(en)
|
2016-04-28 |
2024-09-05 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating patients with familial hypercholesterolemia
|
|
KR102523682B1
(ko)
|
2016-05-02 |
2023-04-19 |
에프. 호프만-라 로슈 아게 |
콘톨스바디 - 단쇄 표적 결합제
|
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック， インコーポレイテッド |
Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法
|
|
AU2017268458B2
(en)
|
2016-05-20 |
2022-07-21 |
Regeneron Pharmaceuticals, Inc. |
Methods for breaking immunological tolerance using multiple guide RNAS
|
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
CN110603266A
(zh)
|
2016-06-02 |
2019-12-20 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
|
|
EP3462853B1
(en)
|
2016-06-03 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Rodents expressing exogenous terminal deoxynucleotidyltransferase
|
|
KR102187751B1
(ko)
|
2016-06-06 |
2020-12-08 |
에프. 호프만-라 로슈 아게 |
눈 잔류가 증가된 안과학용 융합 단백질
|
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
|
GB201610162D0
(en)
|
2016-06-10 |
2016-07-27 |
Imp Innovations Ltd And Inst Pasteur |
Methods
|
|
KR102667023B1
(ko)
|
2016-06-14 |
2024-05-21 |
리제너론 파아마슈티컬스, 인크. |
항-c5 항체 및 이의 용도
|
|
KR102376582B1
(ko)
|
2016-06-17 |
2022-03-18 |
추가이 세이야쿠 가부시키가이샤 |
항-마이오스타틴 항체 및 사용 방법
|
|
WO2017223405A1
(en)
|
2016-06-24 |
2017-12-28 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
|
KR20240113990A
(ko)
|
2016-06-27 |
2024-07-23 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조합
|
|
EP3478717B1
(en)
|
2016-07-04 |
2022-01-05 |
F. Hoffmann-La Roche AG |
Novel antibody format
|
|
US10722558B2
(en)
|
2016-07-15 |
2020-07-28 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
|
EA201990226A1
(ru)
|
2016-07-27 |
2019-08-30 |
Акселерон Фарма Инк. |
Способы и композиции для лечения миелофиброза
|
|
CN109803530A
(zh)
|
2016-07-29 |
2019-05-24 |
瑞泽恩制药公司 |
包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
|
|
EP3492496A4
(en)
|
2016-07-29 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
|
|
EP3494991A4
(en)
|
2016-08-05 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
|
EP3282019A1
(en)
|
2016-08-09 |
2018-02-14 |
Medizinische Universität Wien |
Genotyping and treatment of cancer, in particular chronic lymphocytic leukemia
|
|
EP3496763A1
(en)
|
2016-08-11 |
2019-06-19 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
|
SG11201900746RA
(en)
|
2016-08-12 |
2019-02-27 |
Janssen Biotech Inc |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
EP3497126A4
(en)
|
2016-08-12 |
2020-04-08 |
Janssen Biotech, Inc. |
ANTIBODIES OF FC MODIFIED ANTI-TNFR SUPERFAMILY HAVING IMPROVED AGONIST ACTIVITY AND METHODS OF USE THEREOF
|
|
WO2018039131A1
(en)
|
2016-08-22 |
2018-03-01 |
Protiva Biotherapeutics, Inc. |
Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
|
|
JP2019529371A
(ja)
|
2016-08-29 |
2019-10-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
肺動脈性肺高血圧を処置するための抗グレムリン−１（ｇｒｅｍ１）抗体およびその使用の方法
|
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
|
JP6976315B2
(ja)
|
2016-09-19 |
2021-12-08 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
補体因子に基づくアフィニティークロマトグラフィー
|
|
KR20190052027A
(ko)
|
2016-09-23 |
2019-05-15 |
씨에스엘 리미티드 |
응고 인자 결합 단백질 및 이의 용도
|
|
IL265473B2
(en)
|
2016-09-23 |
2024-01-01 |
Genentech Inc |
Uses of il-13 antagonists for treating atopic dermatitis
|
|
KR102294755B1
(ko)
|
2016-09-30 |
2021-08-31 |
리제너론 파마슈티칼스 인코포레이티드 |
C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물
|
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
|
KR102804118B1
(ko)
|
2016-10-06 |
2025-05-09 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
|
WO2018075954A2
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
AU2017345786B2
(en)
|
2016-10-21 |
2024-08-01 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
SG11201903287PA
(en)
|
2016-10-21 |
2019-05-30 |
Adimab Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
WO2018081648A2
(en)
|
2016-10-29 |
2018-05-03 |
Genentech, Inc. |
Anti-mic antibidies and methods of use
|
|
US12063913B2
(en)
|
2016-10-31 |
2024-08-20 |
National University Corporation Tottori University |
Human antibody-producing non-human animal and method for preparing human antibodies using same
|
|
MA46708B1
(fr)
|
2016-11-02 |
2021-10-29 |
Jounce Therapeutics Inc |
Anticorps anti-pd1 et leurs utilisations
|
|
PL3766343T3
(pl)
|
2016-11-04 |
2022-09-26 |
Regeneron Pharmaceuticals, Inc. |
Zwierzęta inne niż człowiek posiadające zmodyfikowany sposobami inżynierii locus łańcucha lekkiego lambda immunoglobuliny
|
|
KR20190074310A
(ko)
|
2016-11-08 |
2019-06-27 |
리제너론 파마슈티칼스 인코포레이티드 |
스테로이드 및 이의 단백질-접합체
|
|
KR102345175B1
(ko)
|
2016-11-14 |
2021-12-31 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
|
|
CN110036029A
(zh)
|
2016-11-17 |
2019-07-19 |
瑞泽恩制药公司 |
用抗angptl8抗体处理肥胖的方法
|
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
|
WO2018091720A1
(en)
|
2016-11-21 |
2018-05-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
|
JP7071975B2
(ja)
|
2016-11-29 |
2022-05-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
オピオイド嗜癖を避けるための医薬組成物
|
|
JP6951444B2
(ja)
|
2016-11-30 |
2021-10-20 |
クローダ インターナショナル パブリック リミティド カンパニー |
水性バインダ系、コーティング組成物及びコーティング
|
|
WO2018106776A2
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
|
MY198942A
(en)
|
2016-12-07 |
2023-10-03 |
Genentech Inc |
Anti-tau antibodies and methods of use
|
|
WO2018110555A1
(ja)
|
2016-12-13 |
2018-06-21 |
アステラス製薬株式会社 |
抗ヒトｃｄ７３抗体
|
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
|
CA3045970A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
|
AU2017381656B2
(en)
|
2016-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
|
WO2018118713A1
(en)
|
2016-12-22 |
2018-06-28 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
JP7007734B2
(ja)
*
|
2016-12-27 |
2022-02-10 |
国立大学法人群馬大学 |
条件付きノックアウト動物の製造方法
|
|
TW202311284A
(zh)
|
2017-01-03 |
2023-03-16 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
|
|
CN110662421B
(zh)
|
2017-01-19 |
2023-03-24 |
欧莫诺艾比公司 |
来自具有多个重链免疫球蛋白基因座的转基因啮齿类动物的人抗体
|
|
CN118325899A
(zh)
|
2017-01-23 |
2024-07-12 |
瑞泽恩制药公司 |
Hsd17b13变体及其应用
|
|
US10713373B2
(en)
*
|
2017-02-09 |
2020-07-14 |
Lifesite, Inc. |
Computing system with information storage mechanism and method of operation thereof
|
|
KR102660715B1
(ko)
|
2017-02-10 |
2024-04-26 |
리제너론 파마슈티칼스 인코포레이티드 |
면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
|
|
EP3580240A1
(en)
|
2017-02-10 |
2019-12-18 |
H. Hoffnabb-La Roche Ag |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
|
WO2018148660A1
(en)
|
2017-02-10 |
2018-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
JP7227151B2
(ja)
|
2017-03-22 |
2023-02-21 |
ジェネンテック， インコーポレイテッド |
眼障害の治療のために最適化された抗体組成物
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
|
UA125700C2
(uk)
|
2017-04-03 |
2022-05-18 |
Ф. Хоффманн-Ля Рош Аг |
Імунокон'югати антитіла до pd-1 з мутантом il-2
|
|
CA3053360A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antibodies
|
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
|
WO2018195338A1
(en)
|
2017-04-20 |
2018-10-25 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
|
AU2018254586A1
(en)
|
2017-04-21 |
2019-10-17 |
Genentech, Inc. |
Use of KLK5 antagonists for treatment of a disease
|
|
EP3615572A1
(en)
|
2017-04-27 |
2020-03-04 |
Tesaro Inc. |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
|
EP3625251A1
(en)
|
2017-05-15 |
2020-03-25 |
University Of Rochester |
Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
|
|
JP7364471B2
(ja)
|
2017-05-18 |
2023-10-18 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
シクロデキストリンタンパク質薬物コンジュゲート
|
|
IL270894B2
(en)
|
2017-06-01 |
2023-04-01 |
Regeneron Pharma |
Human antibodies to bet v 1 and methods of using them
|
|
WO2018224951A2
(en)
|
2017-06-05 |
2018-12-13 |
Janssen Biotech, Inc. |
Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
|
|
JP7235733B2
(ja)
|
2017-06-05 |
2023-03-08 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｄ－１に特異的に結合する抗体、及び使用方法
|
|
US20190031774A1
(en)
|
2017-06-09 |
2019-01-31 |
Sanofi Biotechnology |
Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
|
|
WO2019005897A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
|
|
KR20240006698A
(ko)
|
2017-07-21 |
2024-01-15 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
IL271818B2
(en)
|
2017-07-21 |
2024-10-01 |
Trianni Inc |
Single chain vh and heavy chain antibodies
|
|
AU2018307744B2
(en)
|
2017-07-24 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-CD8 antibodies and uses thereof
|
|
EP3658581A1
(en)
|
2017-07-24 |
2020-06-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies and peptides to treat hcmv related diseases
|
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
|
PE20200486A1
(es)
|
2017-08-03 |
2020-03-03 |
Alector Llc |
Anticuerpos anti-cd33 y metodos para utilizarlos
|
|
US11021540B2
(en)
|
2017-09-07 |
2021-06-01 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
LT3681911T
(lt)
|
2017-09-11 |
2025-01-10 |
Monash University |
Žmogaus trombino receptorių par4 surišantys baltymai
|
|
EP3690050A4
(en)
|
2017-09-29 |
2021-06-16 |
Chugai Seiyaku Kabushiki Kaisha |
MULTISPECIFIC ANTIGENBINDING MOLECULE WITH BLOOD CLOG FACTOR VIII (FVIII) COFACTOR FUNCTION SUBSTITUATING ACTIVITY AND PHARMACEUTICAL FORMULATION WITH THIS MOLECULE AS THE ACTIVE SUBSTANCE
|
|
CA3076632A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
|
EP3476942B1
(en)
|
2017-10-27 |
2022-01-26 |
Trianni, Inc. |
Long germline dh genes and long hcdr3 antibodies
|
|
KR102694419B1
(ko)
|
2017-10-30 |
2024-08-09 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
|
|
WO2019086395A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Trifab-contorsbody
|
|
EP3704150A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
The compbody - a multivalent target binder
|
|
JP7544597B2
(ja)
|
2017-11-06 |
2024-09-03 |
ジェネンテック， インコーポレイテッド |
がんの診断及び療法
|
|
WO2019094395A2
(en)
|
2017-11-07 |
2019-05-16 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
JP7731196B2
(ja)
|
2017-11-14 |
2025-08-29 |
中外製薬株式会社 |
抗Ｃ１ｓ抗体および使用方法
|
|
EP3717514A1
(en)
|
2017-11-30 |
2020-10-07 |
Regeneron Pharmaceuticals, Inc. |
Anti-trkb monoclonal antibodies and methods of use
|
|
PT3720279T
(pt)
*
|
2017-12-05 |
2022-10-06 |
Regeneron Pharma |
Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos
|
|
EP3724226A1
(en)
|
2017-12-13 |
2020-10-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibody combinations and uses thereof
|
|
WO2019126194A1
(en)
|
2017-12-18 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
Angptl8 assay and uses thereof
|
|
MA51302A
(fr)
|
2017-12-21 |
2021-03-31 |
Hoffmann La Roche |
Anticorps se liant à hla-a2/wt1
|
|
WO2019126472A1
(en)
|
2017-12-22 |
2019-06-27 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
|
US10723798B2
(en)
|
2017-12-22 |
2020-07-28 |
Jounce Therapeutics, Inc. |
Antibodies to LILRB2
|
|
AU2018396964C1
(en)
|
2017-12-28 |
2024-10-03 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against PD-L1
|
|
AU2018396970B2
(en)
|
2017-12-28 |
2025-09-25 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
|
US11440957B2
(en)
|
2017-12-29 |
2022-09-13 |
Alector Llc |
Anti-TMEM106B antibodies and methods of use thereof
|
|
AU2019205542B2
(en)
|
2018-01-08 |
2025-10-23 |
Regeneron Pharmaceuticals, Inc. |
Steroids and antibody-conjugates thereof
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
US20200339686A1
(en)
|
2018-01-16 |
2020-10-29 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
RS61825B1
(sr)
|
2018-01-26 |
2021-06-30 |
Regeneron Pharma |
Anti-tmprss2 antitela i fragmenti koji vezuju antigen
|
|
IL275884B2
(en)
|
2018-01-26 |
2024-11-01 |
Regeneron Pharma |
Human antibodies to influenza hemagglutinin
|
|
US11472874B2
(en)
|
2018-01-31 |
2022-10-18 |
Alector Llc |
Anti-MS4A4A antibodies and methods of use thereof
|
|
US12180285B2
(en)
|
2018-02-01 |
2024-12-31 |
Memorial Sloan Kettering Cancer Center |
Antibodies to galectin-3 and methods of use thereof
|
|
SG11202007390YA
(en)
|
2018-02-08 |
2020-08-28 |
Genentech Inc |
Bispecific antigen-binding molecules and methods of use
|
|
US12364736B2
(en)
|
2018-02-09 |
2025-07-22 |
Acceleron Pharma Inc. |
Methods for treating heterotopic ossification
|
|
AU2019218128A1
(en)
|
2018-02-09 |
2020-09-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
US20200399376A1
(en)
|
2018-02-26 |
2020-12-24 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
AU2019231703A1
(en)
|
2018-03-06 |
2020-10-22 |
Regeneron Pharmaceuticals, Inc. |
Use of PCSK9 inhibitor for reducing cardiovascular risk
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
|
CN112119090B
(zh)
|
2018-03-15 |
2023-01-13 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
|
US11747340B2
(en)
|
2018-03-24 |
2023-09-05 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for identifying HLA-associated tumor peptides
|
|
HUE070158T2
(hu)
|
2018-03-24 |
2025-05-28 |
Regeneron Pharma |
Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
|
|
AU2019242586B2
(en)
|
2018-03-26 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
|
SG11202008848XA
(en)
|
2018-03-26 |
2020-10-29 |
Regeneron Pharma |
Anti-pfrh5 antibodies and antigen-binding fragments thereof
|
|
AR115318A1
(es)
|
2018-03-29 |
2020-12-23 |
Genentech Inc |
Modulación de la actividad lactogénica en células de mamífero
|
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
|
US11840568B2
(en)
|
2018-04-02 |
2023-12-12 |
Mab-Venture Biopharm Co., Ltd. |
Lymphocyte activation gene-3 (LAG-3) binding antibody and use thereof
|
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
|
HRP20250986T1
(hr)
|
2018-04-06 |
2025-10-24 |
Regeneron Pharmaceuticals, Inc. |
Antitijelo agonista leptinskog receptora za upotrebu u povećanju koštane mase kod osobe koja pati od metaboličke disfunkcije ili hipoleptinemije
|
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
|
EP3787678A1
(en)
|
2018-05-03 |
2021-03-10 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
|
SG11202010909RA
(en)
|
2018-05-09 |
2020-12-30 |
Regeneron Pharma |
Anti-msr1 antibodies and methods of use thereof
|
|
DK3802608T3
(da)
|
2018-05-24 |
2025-06-10 |
Janssen Biotech Inc |
Anti-cd3-antistoffer og anvendelser deraf
|
|
CN112703203B
(zh)
|
2018-05-24 |
2025-02-25 |
詹森生物科技公司 |
单特异性和多特异性抗-tmeff2抗体及其用途
|
|
EP3802609A2
(en)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech, Inc. |
Psma binding agents and uses thereof
|
|
AR115418A1
(es)
|
2018-05-25 |
2021-01-13 |
Alector Llc |
ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
|
|
CA3106380A1
(en)
|
2018-05-31 |
2019-12-05 |
Glyconex Inc. |
Therapeutic antibodies
|
|
JP2021525806A
(ja)
|
2018-06-01 |
2021-09-27 |
タユー ファシャ バイオテック メディカル グループ カンパニー， リミテッド |
疾患または状態を処置するための組成物およびそれらの使用
|
|
WO2019227490A1
(en)
|
2018-06-01 |
2019-12-05 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and methods for imaging
|
|
JP2021525927A
(ja)
|
2018-06-01 |
2021-09-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
スパースベクトルベースのマトリクス変換のための方法およびシステム
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
JP7634993B2
(ja)
|
2018-06-19 |
2025-02-25 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗因子ＸＩＩ／ＸＩＩａ抗体およびその使用
|
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
CN112384532B
(zh)
|
2018-06-29 |
2025-01-10 |
艾利妥 |
抗SIRP-β1抗体及其使用方法
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP3820891A1
(en)
|
2018-07-10 |
2021-05-19 |
Regeneron Pharmaceuticals, Inc. |
Modifying binding molecules to minimize pre-existing interactions
|
|
PL3618928T3
(pl)
|
2018-07-13 |
2023-05-02 |
Alector Llc |
Przeciwciała antysortylinowe i sposoby ich stosowania
|
|
CA3103531A1
(en)
|
2018-07-16 |
2020-01-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-il36r antibodies
|
|
JP2021530237A
(ja)
|
2018-07-17 |
2021-11-11 |
ウーマブス ビオメド エセアー |
Ｃａｍｐｙｌｏｂａｃｔｅｒの種に対する抗体
|
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
|
BR112021001214A2
(pt)
|
2018-07-24 |
2021-04-27 |
Medimmune, Llc |
anticorpo dirigido contra o fator de aglutinação a (clfa) de s. aureus
|
|
CN118754986A
(zh)
|
2018-08-10 |
2024-10-11 |
中外制药株式会社 |
抗cd137抗原结合分子及其应用
|
|
CN112839956A
(zh)
|
2018-08-10 |
2021-05-25 |
瑞泽恩制药公司 |
安全有效治疗膝和/或髋疼痛的药物组合物
|
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商２３與我有限公司 |
抗ｉｌ１ｒａｐ抗體及其使用方法
|
|
JP7504871B2
(ja)
|
2018-08-29 |
2024-06-24 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
関節リウマチを有する対象を治療するための方法および組成物
|
|
US12247073B2
(en)
|
2018-08-31 |
2025-03-11 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
|
US12275788B2
(en)
|
2018-09-10 |
2025-04-15 |
Legend Biotech Ireland Limited |
Single-domain antibodies against CD33 and constructs thereof
|
|
US20220053741A1
(en)
|
2018-09-13 |
2022-02-24 |
Regeneron Pharmaceuticals, Inc. |
Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
|
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2020061349A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
TW202028244A
(zh)
|
2018-10-09 |
2020-08-01 |
美商建南德克公司 |
用於確定突觸形成之方法及系統
|
|
US11168133B2
(en)
|
2018-10-09 |
2021-11-09 |
Medimmune, Llc |
Combinations of anti-Staphylococcus aureus antibodies
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
KR20210082207A
(ko)
|
2018-10-23 |
2021-07-02 |
리제너론 파아마슈티컬스, 인크. |
항-npr1 항체 및 이의 용도
|
|
AU2019365238A1
(en)
|
2018-10-24 |
2021-05-13 |
F. Hoffmann-La Roche Ag |
Conjugated chemical inducers of degradation and methods of use
|
|
MY204672A
(en)
|
2018-10-31 |
2024-09-09 |
Astellas Pharma Inc |
Anti-human fn14 antibody
|
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
AU2019384790A1
(en)
|
2018-11-21 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
|
CA3119798A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
|
EP3894543A1
(en)
|
2018-12-14 |
2021-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
GB201820554D0
(en)
|
2018-12-17 |
2019-01-30 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
|
CN113423831B
(zh)
|
2018-12-20 |
2023-03-10 |
瑞泽恩制药公司 |
核酸酶介导的重复扩增
|
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
EA202191656A1
(ru)
|
2018-12-21 |
2021-10-26 |
23Эндми, Инк. |
Анти-il-36 антитела и способы их применения
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
AU2020208193A1
(en)
|
2019-01-14 |
2021-07-29 |
BioNTech SE |
Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
|
|
WO2020154405A2
(en)
|
2019-01-22 |
2020-07-30 |
Genentech, Inc. |
Immunoglobulin a antibodies and methods of production and use
|
|
US12263234B2
(en)
|
2019-01-23 |
2025-04-01 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Anti-PD-L1 diabodies and the use thereof
|
|
JPWO2020153467A1
(ja)
|
2019-01-24 |
2021-12-02 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
|
CA3126117A1
(en)
|
2019-02-01 |
2020-08-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-il2 receptor gamma antigen-binding proteins
|
|
MA54945A
(fr)
|
2019-02-12 |
2021-12-22 |
Regeneron Pharma |
Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
|
|
US12109273B2
(en)
|
2019-02-15 |
2024-10-08 |
Wuxi Xdc Singapore Private Limited |
Process for preparing antibody-drug conjugates with improved homogeneity
|
|
KR102788989B1
(ko)
|
2019-02-15 |
2025-03-31 |
우시 엑스디씨 싱가포르 프라이빗 리미티드 |
동질성이 개선된 항체-약물 콘쥬게이트의 제조방법
|
|
WO2020169472A2
(en)
|
2019-02-18 |
2020-08-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing phenotypic changes in macrophages
|
|
EP3927832A4
(en)
|
2019-02-18 |
2022-11-30 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
GENETICALLY MODIFIED NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS
|
|
CA3130754A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
WO2020172605A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
|
AU2020226865A1
(en)
|
2019-02-22 |
2021-07-29 |
Regeneron Pharmaceuticals, Inc. |
Rodents having genetically modified sodium channels and methods of use thereof
|
|
WO2020176748A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
|
AU2020231308B2
(en)
|
2019-03-01 |
2025-11-27 |
Allogene Therapeutics, Inc. |
DLL3 targeting chimeric antigen receptors and binding agents
|
|
KR20250143873A
(ko)
|
2019-03-08 |
2025-10-02 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
|
CN113795588B
(zh)
|
2019-04-04 |
2025-02-25 |
瑞泽恩制药公司 |
用于在靶向性载体中无瘢痕引入靶向修饰的方法
|
|
IL286905B2
(en)
|
2019-04-04 |
2024-06-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
|
WO2020210551A1
(en)
|
2019-04-10 |
2020-10-15 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies that bind ret and methods of use thereof
|
|
US11136353B2
(en)
|
2019-04-15 |
2021-10-05 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
|
|
MX2021012692A
(es)
|
2019-04-19 |
2021-11-12 |
Genentech Inc |
Anticuerpos anti-mertk y sus metodos de uso.
|
|
MA55717A
(fr)
|
2019-04-19 |
2022-02-23 |
Janssen Biotech Inc |
Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3
|
|
AU2020261411B2
(en)
|
2019-04-26 |
2025-10-02 |
Allogene Therapeutics, Inc. |
Methods of manufacturing allogeneic car T cells
|
|
TWI894144B
(zh)
|
2019-05-01 |
2025-08-21 |
法商賽諾菲生物技術公司 |
藉由投予il-33拮抗劑治療或預防哮喘之方法
|
|
TWI879768B
(zh)
|
2019-05-03 |
2025-04-11 |
美商建南德克公司 |
用抗pd-l1抗體治療癌症之方法
|
|
WO2020227228A2
(en)
|
2019-05-03 |
2020-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
|
CN114206340A
(zh)
|
2019-05-14 |
2022-03-18 |
豪夫迈·罗氏有限公司 |
使用抗cd79b免疫缀合物治疗滤泡性淋巴瘤的方法
|
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
|
WO2020247452A1
(en)
|
2019-06-04 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
|
|
CA3136478A1
(en)
|
2019-06-05 |
2020-12-10 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
|
|
SG11202111256XA
(en)
|
2019-06-07 |
2021-11-29 |
Regeneron Pharma |
Non-human animals comprising a humanized albumin locus
|
|
MX2021015156A
(es)
|
2019-06-11 |
2022-01-18 |
Regeneron Pharma |
Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
|
|
AU2020291527A1
(en)
|
2019-06-11 |
2022-01-20 |
Alector Llc |
Anti-Sortilin antibodies for use in therapy
|
|
US20220251184A1
(en)
|
2019-06-12 |
2022-08-11 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to bone morphogenetic protein 6
|
|
CA3140083A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
|
US20200399372A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
|
|
IL289458B1
(en)
|
2019-06-29 |
2025-10-01 |
Hangzhou Dac Biotech Co Ltd |
Cell-binding conjugated derivative of tubulin molecule and method for its production
|
|
CN114554841B
(zh)
|
2019-07-01 |
2024-06-11 |
特里安尼公司 |
转基因哺乳动物及其使用方法
|
|
JP7744248B2
(ja)
|
2019-07-01 |
2025-09-25 |
トリアニ・インコーポレイテッド |
トランスジェニック哺乳動物およびその使用法
|
|
TW202115115A
(zh)
|
2019-07-02 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
免疫結合物
|
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
|
US12398212B2
(en)
|
2019-07-16 |
2025-08-26 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
|
NZ785553A
(en)
|
2019-07-26 |
2025-07-25 |
Janssen Biotech Inc |
Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
|
|
CN114174342B
(zh)
|
2019-07-31 |
2024-08-16 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
EP4004045A1
(en)
|
2019-07-31 |
2022-06-01 |
F. Hoffmann-La Roche AG |
Antibodies binding to gprc5d
|
|
WO2021022083A2
(en)
|
2019-07-31 |
2021-02-04 |
Alector Llc |
Anti-ms4a4a antibodies and methods of use thereof
|
|
CN114173819A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法
|
|
CN114173816A
(zh)
|
2019-08-05 |
2022-03-11 |
瑞泽恩制药公司 |
通过施用il-4r拮抗剂治疗特应性皮炎的方法
|
|
TWI883032B
(zh)
|
2019-08-12 |
2025-05-11 |
中國大陸商北京恩瑞尼生物科技股份有限公司 |
藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
|
|
KR20220062494A
(ko)
|
2019-08-15 |
2022-05-17 |
얀센 바이오테크 인코포레이티드 |
개선된 단일 사슬 가변 단편을 위한 재료 및 방법
|
|
DK3785536T4
(da)
|
2019-08-28 |
2025-10-27 |
Trianni Inc |
Adam6-knockin-mus
|
|
CA3146616A1
(en)
|
2019-09-12 |
2021-03-18 |
Matthew Dominic CASCINO |
Compositions and methods of treating lupus nephritis
|
|
EP4031579A2
(en)
|
2019-09-18 |
2022-07-27 |
F. Hoffmann-La Roche AG |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
|
US20220348687A1
(en)
|
2019-09-20 |
2022-11-03 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing GenScript Biotech Co., Ltd. |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
|
US11760801B2
(en)
|
2019-09-27 |
2023-09-19 |
Janssen Biotech, Inc. |
Anti-CEACAM antibodies and uses thereof
|
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
|
EP4048693A1
(en)
|
2019-09-27 |
2022-08-31 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
US12441788B2
(en)
|
2019-09-27 |
2025-10-14 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
|
US20240058466A1
(en)
|
2019-10-04 |
2024-02-22 |
TAE Life Sciences |
Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties For Use In Treating Cancer, Immunological Disorders, and Methods Thereof
|
|
MX2022004443A
(es)
|
2019-10-18 |
2022-05-02 |
Genentech Inc |
Metodos para usar inmunoconjugados anti-cd79b para tratar linfoma difuso de linfocitos b grandes.
|
|
CA3153944A1
(en)
|
2019-10-28 |
2021-05-06 |
Alina Baum |
Anti-hemagglutinin antibodies and methods of use thereof
|
|
WO2021092171A1
(en)
|
2019-11-06 |
2021-05-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
|
TWI895295B
(zh)
|
2019-11-12 |
2025-09-01 |
美商方得生醫療公司 |
偵測編碼新生抗原之融合基因之方法
|
|
IL292899A
(en)
|
2019-11-15 |
2022-07-01 |
Hoffmann La Roche |
Prevention of visible particle formation in aqueous protein solutions
|
|
PH12022551208A1
(en)
|
2019-11-18 |
2023-04-24 |
Janssen Biotech Inc |
Vaccines based on mutant calr and jak2 and their uses
|
|
US20230037414A1
(en)
|
2019-11-22 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale |
Inhibitors of adrenomedullin for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
US11479598B2
(en)
|
2019-11-25 |
2022-10-25 |
Mabloc, Inc. |
Anti-yellow fever antibodies, and methods of their generation and use
|
|
EP4069722A1
(en)
|
2019-12-02 |
2022-10-12 |
Regeneron Pharmaceuticals, Inc. |
Peptide-mhc ii protein constructs and uses thereof
|
|
US20210230265A1
(en)
|
2019-12-06 |
2021-07-29 |
Sanofi Biotechnology |
Methods for treating copd by administering an il-33 antagonist
|
|
JP2023504204A
(ja)
|
2019-12-09 |
2023-02-01 |
サノフィ・バイオテクノロジー |
デジタル的に識別されたｉｌ－４／ｉｌ－１３関連障害を治療する方法
|
|
EP3992974A1
(en)
|
2020-11-02 |
2022-05-04 |
Sanofi Biotechnology |
Methods for treating digitally-identified il-4/il-13 related disorders
|
|
CN115066272A
(zh)
|
2019-12-10 |
2022-09-16 |
再生元制药公司 |
Pcsk9抑制剂治疗纯合家族性高胆固醇血症的用途
|
|
AU2020403145B2
(en)
|
2019-12-13 |
2025-06-26 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
|
BR112022011570A2
(pt)
|
2019-12-13 |
2022-12-13 |
Alector Llc |
Anticorpos anti-mertk e métodos de uso dos mesmos
|
|
EP4076666A1
(en)
|
2019-12-18 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to hla-a2/mage-a4
|
|
WO2021119761A1
(en)
|
2019-12-20 |
2021-06-24 |
Hudson Institute of Medical Research |
Cxcl10 binding proteins and uses thereof
|
|
US20230340101A1
(en)
|
2019-12-23 |
2023-10-26 |
Sanofi Biotechnology |
Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist
|
|
KR102645629B1
(ko)
|
2019-12-27 |
2024-03-07 |
추가이 세이야쿠 가부시키가이샤 |
항ctla-4 항체 및 그의 사용
|
|
GB2609554B
(en)
|
2020-01-03 |
2025-08-20 |
Marengo Therapeutics Inc |
Anti-TCR antibody molecules and uses thereof
|
|
EP4088120A1
(en)
|
2020-01-08 |
2022-11-16 |
Regeneron Pharmaceuticals, Inc. |
Use of amino acids to enhance signal in mass spectral analyses
|
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
|
CN115348874A
(zh)
|
2020-01-24 |
2022-11-15 |
里珍纳龙药品有限公司 |
蛋白质-抗病毒化合物偶联物
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
BR112022014176A2
(pt)
|
2020-01-27 |
2022-09-27 |
Regeneron Pharma |
Quantificação multiplexada de etiqueta de massa tandem de modificações pós-traducionais de proteínas
|
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
US12250931B2
(en)
|
2020-01-28 |
2025-03-18 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mouse with a humanized PNPLA3 gene and methods of use
|
|
AU2021214764A1
(en)
|
2020-01-30 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Platform for native liquid chromatography-mass spectrometry
|
|
IL294907A
(en)
|
2020-01-31 |
2022-09-01 |
Regeneron Pharma |
High confidence compound identification by liquid chromatography-mass spectrometry
|
|
EP4096708A1
(en)
|
2020-01-31 |
2022-12-07 |
Genentech, Inc. |
Methods of inducing neoepitope-specific t cells with a pd-1 axis binding antagonist and an rna vaccine
|
|
US20250263466A1
(en)
|
2020-02-03 |
2025-08-21 |
Vir Biotechnology, Inc. |
Antibodies against sars-cov-2 and methods of using the same
|
|
EP3862023A1
(en)
|
2020-02-05 |
2021-08-11 |
Hangzhou DAC Biotech Co, Ltd |
Conjugates of cell-binding molecules with cytotoxic agents
|
|
US20230081547A1
(en)
|
2020-02-07 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized klkb1 locus and methods of use
|
|
AU2021218927B2
(en)
|
2020-02-10 |
2024-12-19 |
Shanghai Escugen Biotechnology Co., Ltd. |
Claudin 18.2 antibody and use thereof
|
|
CN115427457A
(zh)
|
2020-02-10 |
2022-12-02 |
瑞泽恩制药公司 |
抗tmprss2抗体和抗原结合片段
|
|
JP7663883B2
(ja)
|
2020-02-10 |
2025-04-17 |
上海詩健生物科技有限公司 |
Ｃｌｄｎ１８．２抗体及びその使用
|
|
IL295419A
(en)
|
2020-02-11 |
2022-10-01 |
Regeneron Pharma |
Anti-acvr1 antibodies and their uses
|
|
TWI895351B
(zh)
|
2020-02-12 |
2025-09-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
|
US20230135136A1
(en)
|
2020-02-12 |
2023-05-04 |
Janssen Pharmaceutica Nv |
Fgfr tyrosine kinase inhibitors and anti-pdi agents for the treatment of urothelial carcinoma
|
|
CR20220396A
(es)
|
2020-02-14 |
2022-11-14 |
Jounce Therapeutics Inc |
Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
PT3872091T
(pt)
|
2020-02-26 |
2023-09-19 |
Vir Biotechnology Inc |
Anticorpos contra sars-cov-2
|
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
|
KR20220152262A
(ko)
|
2020-03-13 |
2022-11-15 |
제넨테크, 인크. |
항-인터루킨-33 항체 및 이의 용도
|
|
PE20240020A1
(es)
|
2020-03-13 |
2024-01-04 |
Janssen Biotech Inc |
Materiales y metodos para la union de siglec-3/cd33
|
|
TWI867190B
(zh)
|
2020-03-19 |
2024-12-21 |
美商建南德克公司 |
同功型選擇性抗-TGF-β抗體及其使用方法
|
|
EP4125348A1
(en)
|
2020-03-23 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
US11999787B2
(en)
|
2020-03-24 |
2024-06-04 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
|
CA3169908A1
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
|
JP2023520676A
(ja)
|
2020-03-27 |
2023-05-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによりアトピー性皮膚炎を処置するための方法
|
|
JP2023519962A
(ja)
|
2020-03-31 |
2023-05-15 |
アレクトル エルエルシー |
抗ｍｅｒｔｋ抗体及びその使用方法
|
|
JP2023519930A
(ja)
|
2020-04-01 |
2023-05-15 |
ユニバーシティ オブ ロチェスター |
インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体
|
|
JP7116256B1
(ja)
|
2020-04-02 |
2022-08-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
|
|
WO2021203053A1
(en)
|
2020-04-03 |
2021-10-07 |
Vir Biotechnology, Inc. |
Immunotherapy targeting a conserved region in sars coronaviruses
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
CA3175533A1
(en)
|
2020-04-14 |
2021-10-21 |
Davide Corti |
Antibodies against sars-cov-2 and methods of using the same
|
|
CA3173338A1
(en)
|
2020-04-14 |
2021-10-21 |
Eric Shierly |
Ultraviolet monitoring of chromatography performance by orthogonal partial least squares
|
|
CA3168460A1
(en)
|
2020-04-15 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
US11701427B2
(en)
|
2020-04-16 |
2023-07-18 |
Regeneron Pharmaceuticals, Inc. |
Diels-alder conjugation methods
|
|
IL296664A
(en)
|
2020-04-24 |
2022-11-01 |
Hoffmann La Roche |
Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
|
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
TW202216757A
(zh)
|
2020-04-28 |
2022-05-01 |
美國洛克菲勒大學 |
中和性抗ｓａｒｓ－ｃｏｖ－２抗體及其使用方法
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
EP4146283A1
(en)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
|
JP2023525039A
(ja)
|
2020-05-08 |
2023-06-14 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
Ｓａｒｓ－ｃｏｖ－２に対する抗体
|
|
US20230181753A1
(en)
|
2020-05-12 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
|
JP7702428B2
(ja)
|
2020-05-12 |
2025-07-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｇｌｐ１ｒアンタゴニスト抗体およびその使用方法
|
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ． ホフマン－ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司（Ch） |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
|
IL298257A
(en)
|
2020-05-22 |
2023-01-01 |
Regeneron Pharma |
Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
|
|
JP2023527352A
(ja)
|
2020-05-26 |
2023-06-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体及び抗原結合断片
|
|
PE20230389A1
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
|
|
JP2023528375A
(ja)
|
2020-05-29 |
2023-07-04 |
２３アンドミー・インコーポレイテッド |
抗ｃｄ２００ｒ１抗体及びその使用方法
|
|
US20230235075A1
(en)
|
2020-06-02 |
2023-07-27 |
Dynamicure Biotechnology Llc |
Anti-cd93 constructs and uses thereof
|
|
CN115667532A
(zh)
*
|
2020-06-02 |
2023-01-31 |
百奥赛图(北京)医药科技股份有限公司 |
具有共有轻链免疫球蛋白基因座的经遗传修饰的非人动物
|
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
|
WO2021247925A1
(en)
|
2020-06-03 |
2021-12-09 |
Vir Biotechnology, Inc. |
Structure-guided immunotherapy against sars-cov-2
|
|
MX2022015206A
(es)
|
2020-06-08 |
2023-01-05 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso.
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック， インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
|
JP2023530274A
(ja)
|
2020-06-12 |
2023-07-14 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
ＳＡＲＳ－ＣｏＶ－２感染の抗体療法
|
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック， インコーポレイテッド |
抗ｔｉｇｉｔ抗体及びｐｄ－１軸結合アンタゴニストを用いた治療
|
|
KR20230026407A
(ko)
|
2020-06-18 |
2023-02-24 |
리제너론 파아마슈티컬스, 인크. |
액티빈 a 항체 제형 및 이의 사용 방법
|
|
CN116234824A
(zh)
|
2020-06-22 |
2023-06-06 |
阿尔米雷尔有限公司 |
抗il-36抗体及其使用方法
|
|
EP4172192A1
(en)
|
2020-06-24 |
2023-05-03 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
|
JP2023541216A
(ja)
|
2020-06-25 |
2023-09-29 |
ヒューマブ カンパニー リミテッド |
ヘテロ接合型トランスジェニック動物
|
|
AU2021300129A1
(en)
|
2020-07-01 |
2022-12-08 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating allergy using anti-Bet v 1 antibodies
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
EP4178529A1
(en)
|
2020-07-07 |
2023-05-17 |
F. Hoffmann-La Roche AG |
Alternative surfactants as stabilizers for therapeutic protein formulations
|
|
AU2021308190A1
(en)
|
2020-07-13 |
2023-02-02 |
Regeneron Pharmaceuticals, Inc. |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
|
PE20231300A1
(es)
|
2020-07-17 |
2023-08-24 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
|
MX2023000888A
(es)
|
2020-07-21 |
2023-02-22 |
Genentech Inc |
Inductores quimicos de degradacion conjugados con anticuerpo de brm y metodos de estos.
|
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
|
AU2021315665A1
(en)
|
2020-07-29 |
2023-03-16 |
Dynamicure Biotechnology Llc |
Anti-CD93 constructs and uses thereof
|
|
WO2022024024A2
(en)
|
2020-07-29 |
2022-02-03 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
|
CA3188213A1
(en)
|
2020-08-07 |
2022-02-10 |
Robert C. Pordy |
Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor
|
|
EP3954393A1
(en)
|
2020-08-13 |
2022-02-16 |
Bioasis Technologies Inc. |
Combination therapies for delivery across the blood brain barrier
|
|
WO2022046925A1
(en)
|
2020-08-26 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
|
IL301137A
(en)
|
2020-09-11 |
2023-05-01 |
Regeneron Pharma |
Identification and production of antigen-specific antibodies
|
|
KR20230070337A
(ko)
|
2020-09-14 |
2023-05-22 |
리제너론 파마슈티칼스 인코포레이티드 |
Glp1 펩티도미메틱을 포함하는 항체-약물 접합체 및 이의 용도
|
|
EP4211165A1
(en)
|
2020-09-14 |
2023-07-19 |
Ichnos Sciences SA |
Antibodies that bind to il1rap and uses thereof
|
|
EP4217385A2
(en)
|
2020-09-28 |
2023-08-02 |
VIR Biotechnology, Inc. |
Antibodies against sars-cov-2
|
|
CN118126189A
(zh)
|
2020-09-28 |
2024-06-04 |
安济盛生物医药有限公司 |
抗硬骨抑素构建体及其用途
|
|
BR112023004020A2
(pt)
|
2020-10-05 |
2023-04-25 |
Sanofi Biotechnology |
Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r
|
|
CN116406291A
(zh)
|
2020-10-05 |
2023-07-07 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
US20240268360A1
(en)
|
2020-10-08 |
2024-08-15 |
Humab Co., Ltd. |
Method for preparing transgenic non-human animal having genome including humanized immunoglobulin gene locus
|
|
KR20230086765A
(ko)
|
2020-10-13 |
2023-06-15 |
얀센 바이오테크 인코포레이티드 |
분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법
|
|
AU2021360782A1
(en)
|
2020-10-14 |
2023-06-08 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
|
IL300024A
(en)
|
2020-10-20 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
|
|
TW202233672A
(zh)
|
2020-10-22 |
2022-09-01 |
美商健生生物科技公司 |
包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
|
|
CN116406379A
(zh)
|
2020-10-22 |
2023-07-07 |
瑞泽恩制药公司 |
抗fgfr2抗体和其使用方法
|
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
IL302217A
(en)
|
2020-11-04 |
2023-06-01 |
Genentech Inc |
Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies and anti-CD79B drug antibody conjugates
|
|
TWI874719B
(zh)
|
2020-11-04 |
2025-03-01 |
美商建南德克公司 |
用抗cd20/抗cd3雙特異性抗體進行治療之給藥
|
|
TW202227481A
(zh)
|
2020-11-04 |
2022-07-16 |
美國洛克菲勒大學 |
中和抗sars-cov-2抗體
|
|
CA3200860A1
(en)
|
2020-11-16 |
2022-05-19 |
Astellas Pharma Inc. |
Anti-tspan8/anti-cd3 bispecific antibody and anti-tspan8 antibody
|
|
AU2021376837A1
(en)
|
2020-11-16 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
|
WO2022109317A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Anti-influenza antibodies and combinations thereof
|
|
WO2022109291A1
(en)
|
2020-11-23 |
2022-05-27 |
Vir Biotechnology, Inc. |
Antibodies against influenza a viruses
|
|
JP2023551668A
(ja)
|
2020-11-23 |
2023-12-12 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
インフルエンザのノイラミニダーゼに対する広域中和抗体
|
|
JP2023550785A
(ja)
|
2020-11-25 |
2023-12-05 |
ヴィア・バイオテクノロジー・インコーポレイテッド |
複数のベータコロナウイルスに結合する抗体
|
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
|
US20240023526A1
(en)
|
2020-12-09 |
2024-01-25 |
Trianni, Inc. |
Heavy chain-only antibodies
|
|
CN116848254A
(zh)
|
2020-12-16 |
2023-10-03 |
瑞泽恩制药公司 |
表达人源化Fcα受体的小鼠
|
|
EP4263609A1
(en)
|
2020-12-17 |
2023-10-25 |
F. Hoffmann-La Roche AG |
Anti-hla-g antibodies and use thereof
|
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
|
WO2022133239A1
(en)
|
2020-12-18 |
2022-06-23 |
Regeneron Pharmaceuticals, Inc. |
Immunoglobulin proteins that bind to npr1 agonists
|
|
JP2024503996A
(ja)
|
2020-12-20 |
2024-01-30 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
生体分子中のスクランブルジスルフィドを同定するための方法
|
|
US12371487B2
(en)
|
2020-12-23 |
2025-07-29 |
Regeneron Pharmaceuticals, Inc. |
Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
|
|
EP4559939A3
(en)
|
2020-12-23 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses therof
|
|
US20220220211A1
(en)
|
2021-01-08 |
2022-07-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
|
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
|
AU2022207252A1
(en)
|
2021-01-13 |
2023-08-03 |
Astellas Pharma Inc. |
MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14
|
|
EP4277926A1
(en)
|
2021-01-15 |
2023-11-22 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
WO2022159842A1
(en)
|
2021-01-25 |
2022-07-28 |
Vir Biotechnology, Inc. |
Antibody combination therapies for sars-cov-2 infection
|
|
KR20230135627A
(ko)
|
2021-01-25 |
2023-09-25 |
리제너론 파아마슈티컬스, 인크. |
항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
|
|
JP2024504758A
(ja)
|
2021-01-28 |
2024-02-01 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｐｓｍａ結合タンパク質及びその使用
|
|
CA3210502A1
(en)
|
2021-02-09 |
2022-08-18 |
Humabs Biomed Sa |
Antibodies against respiratory syncytial virus, human metapneumovirus and pneumonia virus of mice and methods of using the same
|
|
CA3209136A1
(en)
|
2021-02-09 |
2022-08-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
|
EP4301418A1
(en)
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
|
EP4301472A1
(en)
|
2021-03-05 |
2024-01-10 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
|
AR125074A1
(es)
|
2021-03-12 |
2023-06-07 |
Genentech Inc |
Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
|
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
US20240174746A1
(en)
|
2021-03-18 |
2024-05-30 |
Alector Llc |
Anti-tmem106b antibodies and methods of use thereof
|
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
|
WO2022204202A1
(en)
|
2021-03-23 |
2022-09-29 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
|
IL306103A
(en)
|
2021-03-24 |
2023-11-01 |
Janssen Biotech Inc |
The antibody targets CD22 and CD79B
|
|
EP4314056A1
(en)
|
2021-03-24 |
2024-02-07 |
Janssen Biotech, Inc. |
Proteins comprising cd3 antigen binding domains and uses thereof
|
|
JP2024511424A
(ja)
|
2021-03-25 |
2024-03-13 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗ｉｇｆｂｐ７構築物およびその使用
|
|
AU2022249328A1
(en)
|
2021-03-31 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
|
|
AR125255A1
(es)
|
2021-04-02 |
2023-06-28 |
Regeneron Pharma |
Métodos de predicción y modulación de la glicación de una proteína
|
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
|
US20240199725A1
(en)
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
|
CN117177993B
(zh)
|
2021-04-20 |
2025-06-20 |
瑞泽恩制药公司 |
针对artemin的人抗体及其使用方法
|
|
JP7365654B2
(ja)
|
2021-04-22 |
2023-10-20 |
アステラス製薬株式会社 |
抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体
|
|
WO2022228706A1
(en)
|
2021-04-30 |
2022-11-03 |
F. Hoffmann-La Roche Ag |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
|
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
|
|
EP4334353A1
(en)
|
2021-05-04 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
JP2024516996A
(ja)
|
2021-05-05 |
2024-04-18 |
トリアニ・インコーポレイテッド |
トランスジェニック哺乳動物およびその使用方法
|
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
|
WO2022240877A1
(en)
|
2021-05-11 |
2022-11-17 |
Regeneron Pharmaceuticals, Inc. |
Anti-tmprss6 antibodies and uses thereof
|
|
BR112023023622A2
(pt)
|
2021-05-12 |
2024-02-06 |
Genentech Inc |
Métodos para tratar linfoma difuso, kits, imunoconjugados, polatuzumabe vedotina e imunoconjugado para uso
|
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
|
CA3218489A1
(en)
|
2021-05-24 |
2022-12-01 |
Vir Biotechnology, Inc. |
Engineered polypeptides
|
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
|
BR112023025738A2
(pt)
|
2021-06-09 |
2024-02-27 |
Hoffmann La Roche |
Combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, uso de uma combinação de um inibidor de braf e um antagonista de ligação ao eixo pd-1, método para o tratamento ou profilaxia de câncer, composição farmacêutica e invenção
|
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
|
JP2024527493A
(ja)
|
2021-06-16 |
2024-07-25 |
アレクトル エルエルシー |
一価の抗ＭｅｒＴＫ抗体及びその使用方法
|
|
EP4355785A1
(en)
|
2021-06-17 |
2024-04-24 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
CR20240026A
(es)
|
2021-06-25 |
2024-03-14 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-ctla-4
|
|
JP7477127B2
(ja)
|
2021-06-25 |
2024-05-01 |
中外製薬株式会社 |
抗ｃｔｌａ－４抗体の使用
|
|
EP4367134A1
(en)
|
2021-07-05 |
2024-05-15 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
|
IL310012A
(en)
|
2021-07-14 |
2024-03-01 |
Regeneron Pharma |
Antibodies against SARS-COV-2 spike glycoprotein and antigen-binding fragments
|
|
AU2022310847A1
(en)
|
2021-07-14 |
2024-01-25 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
|
KR20240036570A
(ko)
|
2021-07-22 |
2024-03-20 |
에프. 호프만-라 로슈 아게 |
이종이량체 Fc 도메인 항체
|
|
EP4373576A1
(en)
|
2021-07-22 |
2024-05-29 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
|
AU2022316939A1
(en)
|
2021-07-26 |
2024-03-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
|
JP2024529960A
(ja)
|
2021-07-28 |
2024-08-14 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
タンパク質－抗ウイルス化合物コンジュゲート
|
|
CN117794953A
(zh)
|
2021-08-03 |
2024-03-29 |
豪夫迈·罗氏有限公司 |
双特异性抗体及使用方法
|
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
|
US20230167171A1
(en)
|
2021-08-23 |
2023-06-01 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
EP4392454A4
(en)
|
2021-08-27 |
2025-10-15 |
Janssen Biotech Inc |
ANTI-PSMA ANTIBODIES AND THEIR USES
|
|
AU2022339767A1
(en)
|
2021-08-30 |
2024-04-11 |
Lassen Therapeutics, Inc. |
Anti-il-11rα antibodies
|
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
|
US20240400652A1
(en)
|
2021-09-01 |
2024-12-05 |
Vir Biotechnology, Inc. |
Antibody therapies for sars-cov-2 infection in pediatric subjects
|
|
WO2023034871A1
(en)
|
2021-09-01 |
2023-03-09 |
Vir Biotechnology, Inc. |
High concentration antibody therapies for sars-cov-2 infection
|
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
|
WO2023039442A1
(en)
|
2021-09-08 |
2023-03-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibody combination therapies for sars-cov-2 infection
|
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
|
WO2023056403A1
(en)
|
2021-09-30 |
2023-04-06 |
Genentech, Inc. |
Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
|
|
US20250320520A1
(en)
|
2021-10-01 |
2025-10-16 |
Abcellera Biologics Inc. |
Trangenic rodents for cell line identification and enrichment
|
|
AU2022361184A1
(en)
|
2021-10-08 |
2024-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
Method for preparing prefilled syringe formulation
|
|
CR20240155A
(es)
|
2021-10-14 |
2024-05-10 |
Hoffmann La Roche |
Nuevos inmunoconjugados de interleucina-7
|
|
EP4429706A1
(en)
|
2021-10-14 |
2024-09-18 |
F. Hoffmann-La Roche AG |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
|
WO2023069919A1
(en)
|
2021-10-19 |
2023-04-27 |
Alector Llc |
Anti-cd300lb antibodies and methods of use thereof
|
|
CN119137149A
(zh)
|
2021-10-20 |
2024-12-13 |
赛诺菲生物技术公司 |
用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
|
|
JP2024539157A
(ja)
|
2021-10-22 |
2024-10-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
第ｘｉ因子ａ２ドメイン結合抗体及びそれらの使用方法
|
|
EP4423271A2
(en)
|
2021-10-28 |
2024-09-04 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
AU2021362997A1
(en)
|
2021-11-03 |
2024-05-16 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
JP2024543248A
(ja)
|
2021-11-10 |
2024-11-20 |
トリアニ・インコーポレイテッド |
トランスジェニック哺乳動物およびその使用方法
|
|
JP2024544885A
(ja)
|
2021-11-10 |
2024-12-05 |
ジェネンテック， インコーポレイテッド |
抗インターロイキン－３３抗体及びその使用
|
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
|
WO2023092052A1
(en)
|
2021-11-19 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
|
AU2022392829A1
(en)
|
2021-11-22 |
2024-07-11 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
|
MX2024006387A
(es)
|
2021-12-01 |
2024-06-04 |
Chugai Pharmaceutical Co Ltd |
Metodo para preparar formulacion que contiene anticuerpo.
|
|
EP4444416A1
(en)
|
2021-12-06 |
2024-10-16 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
|
IL312971A
(en)
|
2021-12-08 |
2024-07-01 |
Regeneron Pharma |
Mutant myocilin disease model and uses thereof
|
|
CN118488965A
(zh)
|
2021-12-17 |
2024-08-13 |
上海复宏汉霖生物技术股份有限公司 |
抗ox40抗体、多特异性抗体及其使用方法
|
|
CA3240565A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies and methods of use
|
|
IL313897A
(en)
|
2021-12-30 |
2024-08-01 |
Regeneron Pharma |
Methods for reducing atopic dermatitis by administering an IL-4/IL-13 antagonist
|
|
MX2024008640A
(es)
|
2022-01-12 |
2024-07-24 |
Regeneron Pharma |
Analogos de camptotecina conjugados a un residuo de glutamina en una proteina y su uso.
|
|
MX2024008361A
(es)
|
2022-01-14 |
2024-09-10 |
Regeneron Pharma |
Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
|
|
TW202340251A
(zh)
|
2022-01-19 |
2023-10-16 |
美商建南德克公司 |
抗ｎｏｔｃｈ２抗體及結合物及其使用方法
|
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
AU2023212994A1
(en)
|
2022-01-28 |
2024-08-08 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
CA3242731A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertions for treatment of pompe disease
|
|
EP4475671A1
(en)
|
2022-02-07 |
2024-12-18 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
WO2023152581A1
(en)
|
2022-02-09 |
2023-08-17 |
Janssen Biotech, Inc. |
Method of treating cancer with psmaxcd3 antibody
|
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
|
KR20240144138A
(ko)
|
2022-02-11 |
2024-10-02 |
리제너론 파마슈티칼스 인코포레이티드 |
4r 타우 표적화제를 스크리닝하기 위한 조성물 및 방법
|
|
TW202337497A
(zh)
|
2022-02-18 |
2023-10-01 |
中國大陸商重慶明道浩悅生物科技有限公司 |
鼻內調配物及抗sars-cov-2棘蛋白抗體
|
|
EP4489790A1
(en)
|
2022-03-10 |
2025-01-15 |
Vivasor, Inc. |
Antibody-drug conjugates and uses thereof
|
|
AU2023238766A1
(en)
|
2022-03-23 |
2024-07-25 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
|
AU2023240941A1
(en)
|
2022-03-25 |
2024-09-19 |
Shanghai Henlius Biologics Co., Ltd. |
Anti-msln antibodies and methods of use
|
|
JP2025512824A
(ja)
|
2022-04-01 |
2025-04-22 |
ジェネンテック， インコーポレイテッド |
抗ｆｃｒｈ５／抗ｃｄ３二重特異性抗体による処置のための投与
|
|
WO2023201256A1
(en)
|
2022-04-12 |
2023-10-19 |
Vir Biotechnology, Inc. |
High dose antibody therapies for sars-cov-2 infection
|
|
CA3255366A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
|
|
KR20250005335A
(ko)
|
2022-04-26 |
2025-01-09 |
추가이 세이야쿠 가부시키가이샤 |
의약 제제 함유 필터 내장 시린지
|
|
US20240002491A1
(en)
|
2022-04-27 |
2024-01-04 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
|
AU2023262112A1
(en)
|
2022-04-29 |
2024-10-31 |
Purinomia Biotech, Inc. |
Methods and compositions for treating eosinophil driven diseases and disorders
|
|
KR20250006932A
(ko)
|
2022-05-03 |
2025-01-13 |
제넨테크, 인크. |
항-Ly6E 항체, 면역접합체 및 이들의 용도
|
|
IL316738A
(en)
|
2022-05-11 |
2024-12-01 |
Genentech Inc |
Dosage for treatment with anti-FCRH5/anti-CD3 bispecific antibodies
|
|
WO2023230448A1
(en)
|
2022-05-23 |
2023-11-30 |
Vir Biotechnology, Inc. |
Combination immunotherapy for influenza
|
|
CA3256285A1
(en)
|
2022-05-23 |
2023-11-30 |
Humabs Biomed Sa |
Broadly neutralizing antibodies directed against influenza neuraminidase
|
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
|
KR20250022049A
(ko)
|
2022-06-07 |
2025-02-14 |
제넨테크, 인크. |
항-pd-l1 길항제 및 항-tigit 길항제 항체를 포함하는, 폐암 치료의 효율을 결정하는 방법
|
|
WO2023245078A1
(en)
|
2022-06-15 |
2023-12-21 |
Humabs Biomed Sa |
Anti-parvovirus antibodies and uses thereof
|
|
WO2024006472A1
(en)
|
2022-06-30 |
2024-01-04 |
Vir Biotechnology, Inc. |
Antibodies that bind to multiple sarbecoviruses
|
|
AU2023304436A1
(en)
|
2022-07-08 |
2025-02-20 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating pediatric eosinophilic esophagitis by administering an il-4r antagonist
|
|
EP4554977A1
(en)
|
2022-07-12 |
2025-05-21 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
|
JP2025523020A
(ja)
|
2022-07-13 |
2025-07-17 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
CN119604530A
(zh)
|
2022-07-19 |
2025-03-11 |
基因泰克公司 |
用抗fcrh5/抗cd3双特异性抗体进行治疗的给药
|
|
CA3260622A1
(en)
|
2022-07-19 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
GENETICALLY MODIFIED ANIMAL MODEL AND ITS USE TO MODEL THE HUMAN IMMUNE SYSTEM
|
|
MA71559A
(fr)
|
2022-07-22 |
2025-05-30 |
Genentech, Inc. |
Molécules de liaison à l'antigène anti-steap1 et leurs utilisations
|
|
JP2025526405A
(ja)
|
2022-07-27 |
2025-08-13 |
ヒューマブス・バイオメッド・ソシエテ・アノニム |
Ｒｓｖ及びｍｐｖパラミクソウイルスに対する広域中和抗体
|
|
US20240052051A1
(en)
|
2022-07-29 |
2024-02-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:payload fusions and methods of use thereof
|
|
WO2024026447A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Anti-gpnmb antibodies and methods of use thereof
|
|
AU2023316021A1
(en)
|
2022-07-29 |
2025-03-06 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
IL318625A
(en)
|
2022-07-29 |
2025-03-01 |
Regeneron Pharma |
Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
|
|
JP2025528752A
(ja)
|
2022-07-29 |
2025-09-02 |
アレクトル エルエルシー |
トランスフェリン受容体抗原結合ドメイン及びその使用法
|
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
|
WO2024044770A1
(en)
|
2022-08-26 |
2024-02-29 |
Core Biotherapeutics, Inc. |
Oligonucleotides for the treatment of breast cancer
|
|
CN120091829A
(zh)
|
2022-08-29 |
2025-06-03 |
赛诺菲生物技术公司 |
通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
|
|
JP2025531738A
(ja)
|
2022-09-01 |
2025-09-25 |
ジェネンテック， インコーポレイテッド |
膀胱がんの治療方法及び診断方法
|
|
EP4584296A1
(en)
|
2022-09-07 |
2025-07-16 |
Dynamicure Biotechnology LLC |
Anti-vista constructs and uses thereof
|
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
|
IL319122A
(en)
|
2022-09-28 |
2025-04-01 |
Regeneron Pharma |
Different antibody-resistant receptors improve cell-based therapies
|
|
US20240224964A9
(en)
|
2022-09-29 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
JP2025533849A
(ja)
|
2022-10-07 |
2025-10-09 |
ジェネンテック， インコーポレイテッド |
抗ｃ－ｃモチーフケモカイン受容体８（ｃｃｒ８）抗体を用いてがんを処置する方法
|
|
CN115724975A
(zh)
|
2022-10-20 |
2023-03-03 |
江苏荃信生物医药股份有限公司 |
抗人白介素36受体单克隆抗体及其应用
|
|
WO2024086796A1
(en)
|
2022-10-20 |
2024-04-25 |
Alector Llc |
Anti-ms4a4a antibodies with amyloid-beta therapies
|
|
IL320355A
(en)
|
2022-10-25 |
2025-06-01 |
Genentech Inc |
Therapeutic and diagnostic methods for multiple myeloma
|
|
WO2024092133A1
(en)
|
2022-10-27 |
2024-05-02 |
Regeneron Pharmaceuticals, Inc. |
Anti-acvr1 antibodies and their use in the treatment of trauma-induced heterotopic ossification
|
|
KR20250096792A
(ko)
|
2022-11-01 |
2025-06-27 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여하여 손 및 발 피부염을 치료하기 위한 방법
|
|
US20240165227A1
(en)
|
2022-11-04 |
2024-05-23 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
|
EP4612184A1
(en)
|
2022-11-04 |
2025-09-10 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
US20240190996A1
(en)
|
2022-11-07 |
2024-06-13 |
Regeneron Pharmaceuticals, Inc. |
Factor xi catalytic domain-binding antibodies and methods of use thereof
|
|
AU2023375342A1
(en)
|
2022-11-08 |
2025-04-24 |
F. Hoffmann-La Roche Ag |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
|
WO2024107759A2
(en)
|
2022-11-14 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
|
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
WO2024112818A1
(en)
|
2022-11-22 |
2024-05-30 |
Humabs Biomed Sa |
Engineered anti-sars-cov-2 antibodies and uses thereof
|
|
AU2023384154A1
(en)
|
2022-11-23 |
2025-07-03 |
Alan IRVINE |
Methods for improving bone growth by administering an il-4r antagonist
|
|
TW202440623A
(zh)
|
2022-11-28 |
2024-10-16 |
美商艾洛基因醫療公司 |
靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途
|
|
WO2024118998A2
(en)
|
2022-12-01 |
2024-06-06 |
Vir Biotechnology, Inc. |
Engineered anti-sars-cov-2 antibodies and methods of using the same
|
|
EP4588936A1
(en)
|
2022-12-08 |
2025-07-23 |
Changchun Bcht Biotechnology Co. |
Antibodies specifically binding to rsv
|
|
WO2024129594A1
(en)
|
2022-12-12 |
2024-06-20 |
Genentech, Inc. |
Optimizing polypeptide sialic acid content
|
|
WO2024137381A1
(en)
|
2022-12-19 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies for treating sars-cov-2 infection
|
|
AU2023407365A1
(en)
|
2022-12-21 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|
|
EP4638502A2
(en)
|
2022-12-21 |
2025-10-29 |
Genzyme Corporation |
Anti-pd-1×4-1bb binding proteins
|
|
WO2024138151A1
(en)
|
2022-12-22 |
2024-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Ebolavirus (sudan and zaire) antibodies from non-human primates and human vaccinees
|
|
TW202434642A
(zh)
|
2023-01-06 |
2024-09-01 |
美商拉森醫療公司 |
用於治療甲狀腺眼病之抗ＩＬ—１１Ｒα抗體
|
|
KR20250133728A
(ko)
|
2023-01-06 |
2025-09-08 |
라센 테라퓨틱스, 인코포레이티드 |
항-il-18bp 항체
|
|
WO2024148241A1
(en)
|
2023-01-06 |
2024-07-11 |
Lassen Therapeutics 1, Inc. |
Anti-il-18bp antibodies
|
|
WO2024148232A2
(en)
|
2023-01-06 |
2024-07-11 |
Alector Llc |
Anti-il18 binding protein antibodies and methods of use thereof
|
|
US20240247069A1
(en)
|
2023-01-13 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
TWI897189B
(zh)
|
2023-01-18 |
2025-09-11 |
美商基利科學股份有限公司 |
具有經改變重鏈基因座之嵌合基因轉殖免疫球蛋白小鼠及其製造及使用方法
|
|
CR20250338A
(es)
|
2023-01-18 |
2025-09-02 |
Genentech Inc |
Anticuerpos multiespecíficos y usos de estos
|
|
AR131635A1
(es)
|
2023-01-20 |
2025-04-16 |
Hoffmann La Roche |
Inmunoconjugados
|
|
AR131856A1
(es)
|
2023-02-16 |
2025-05-07 |
Sanofi Sa |
Proteínas de unión a cd40
|
|
EP4665410A1
(en)
|
2023-02-17 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
|
WO2024191785A1
(en)
|
2023-03-10 |
2024-09-19 |
Genentech, Inc. |
Fusions with proteases and uses thereof
|
|
WO2024192201A1
(en)
|
2023-03-15 |
2024-09-19 |
Regeneron Pharmaceuticals, Inc. |
Methods for obtaining antibody molecules with high affinity
|
|
US20240360232A1
(en)
|
2023-03-22 |
2024-10-31 |
Sanofi Biotechnology |
Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
|
|
TW202502820A
(zh)
|
2023-03-27 |
2025-01-16 |
美商再生元醫藥公司 |
藉由投予ｉｌ—４ｒ拮抗劑治療嗜酸性球性胃腸炎之方法
|
|
WO2024206788A1
(en)
|
2023-03-31 |
2024-10-03 |
Genentech, Inc. |
Anti-alpha v beta 8 integrin antibodies and methods of use
|
|
WO2024211211A1
(en)
|
2023-04-03 |
2024-10-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of improving transplant survival using il-2 receptor gamma chain antibodies
|
|
WO2024211235A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211234A1
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
WO2024211236A2
(en)
|
2023-04-05 |
2024-10-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
CN121241064A
(zh)
|
2023-04-10 |
2025-12-30 |
维尔生物科技公司 |
与多种沙贝病毒结合的抗体
|
|
CN121038814A
(zh)
|
2023-04-14 |
2025-11-28 |
中外制药株式会社 |
用于稳定含蛋白质药物制剂的方法
|
|
CN121263210A
(zh)
|
2023-04-17 |
2026-01-02 |
沛科生物公司 |
抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
|
|
AU2024270495A1
(en)
|
2023-05-05 |
2025-10-09 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
AR132623A1
(es)
|
2023-05-08 |
2025-07-16 |
Hoffmann La Roche |
PROTEÍNAS DE FUSIÓN DE INTERFERÓN a DIRIGIDAS Y MÉTODOS DE USO
|
|
AU2024268933A1
(en)
|
2023-05-10 |
2025-11-20 |
Chugai Seiyaku Kabushiki Kaisha |
Methods and compositions for treating cancer
|
|
WO2024238537A1
(en)
|
2023-05-16 |
2024-11-21 |
F. Hoffmann-La Roche Ag |
Pd-1 -regulated il-2 immunocytokine and uses thereof
|
|
WO2024236156A1
(en)
|
2023-05-17 |
2024-11-21 |
Institut National de la Santé et de la Recherche Médicale |
Anti-cathepsin-d antibodies
|
|
TW202448933A
(zh)
|
2023-05-31 |
2024-12-16 |
美商建南德克公司 |
用抗轉化生長因子β３抗體治療ＴＧＦβ相關病症之方法
|
|
WO2024258743A1
(en)
|
2023-06-13 |
2024-12-19 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
US20240415103A1
(en)
|
2023-06-16 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2024263761A1
(en)
|
2023-06-22 |
2024-12-26 |
Genentech, Inc. |
Antibodies and uses thereof
|
|
TW202504929A
(zh)
|
2023-06-22 |
2025-02-01 |
美商建南德克公司 |
用於癌症治療之方法及組成物
|
|
WO2025010424A1
(en)
|
2023-07-06 |
2025-01-09 |
Vir Biotechnology, Inc. |
Antibodies against staphylococcus antigens and methods of using the same
|
|
WO2025012417A1
(en)
|
2023-07-13 |
2025-01-16 |
Institut National de la Santé et de la Recherche Médicale |
Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
|
|
WO2025015321A1
(en)
|
2023-07-13 |
2025-01-16 |
Vir Biotechnology, Inc. |
Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
|
|
WO2025019789A1
(en)
|
2023-07-19 |
2025-01-23 |
Regeneron Pharmaceuticals, Inc. |
ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
|
|
TW202513801A
(zh)
|
2023-07-28 |
2025-04-01 |
美商雷傑納榮製藥公司 |
用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
|
|
TW202519551A
(zh)
|
2023-07-28 |
2025-05-16 |
美商雷傑納榮製藥公司 |
用於治療酸性神經髓磷脂酶缺乏症之抗ＴｆＲ：酸性神經髓磷脂酶
|
|
US20250136688A1
(en)
|
2023-08-07 |
2025-05-01 |
Janssen Biotech, Inc. |
Stabilized cd3 antigen binding agents and methods of use thereof
|
|
WO2025034715A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Gucy2c antibodies and uses thereof
|
|
WO2025032158A1
(en)
|
2023-08-08 |
2025-02-13 |
Institut National de la Santé et de la Recherche Médicale |
Method to treat tauopathies
|
|
WO2025049591A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-cxcr4 antibodies and uses thereof
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025045250A1
(en)
|
2023-09-03 |
2025-03-06 |
Kira Pharmaceuticals (Us) Llc |
Anti-human factor d antibody constructs and uses thereof
|
|
WO2025064738A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Dntt 250-258 off-target peptides and uses thereof
|
|
WO2025064761A1
(en)
|
2023-09-22 |
2025-03-27 |
Regeneron Pharmaceuticals, Inc. |
Kras10-18 g12d off-target peptides and uses thereof
|
|
AR133909A1
(es)
|
2023-09-25 |
2025-11-12 |
Hoffmann La Roche |
ANTICUERPO QUE SE UNE A C3bBb
|
|
WO2025073890A1
(en)
|
2023-10-06 |
2025-04-10 |
Institut National de la Santé et de la Recherche Médicale |
Method to capture circulating tumor extracellular vesicles
|
|
WO2025096921A1
(en)
|
2023-11-03 |
2025-05-08 |
Regeneron Pharmaceuticals, Inc. |
Peptide acids as a glp1r agonist and antibody-drug conjugates thereof
|
|
WO2025106474A1
(en)
|
2023-11-14 |
2025-05-22 |
Genentech, Inc. |
Therapeutic and diagnostic methods for treating cancer with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2025113643A1
(en)
|
2023-12-01 |
2025-06-05 |
Gilead Sciences Inc. |
Anti-fap-light fusion protein and use thereof
|
|
WO2025117384A1
(en)
|
2023-12-01 |
2025-06-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly neutralizing influenza hemagglutinin stem-directed antibodies
|
|
WO2025125386A1
(en)
|
2023-12-14 |
2025-06-19 |
F. Hoffmann-La Roche Ag |
Antibodies that bind to folr1 and methods of use
|
|
WO2025133042A2
(en)
|
2023-12-22 |
2025-06-26 |
F. Hoffmann-La Roche Ag |
Activatable fusion proteins and methods of use
|
|
WO2025151806A1
(en)
|
2024-01-11 |
2025-07-17 |
Regeneron Pharmaceuticals, Inc. |
P75 neurotrophin receptor (p75ntr)-binding proteins and p75ntr-mediated delivery to the nervous system
|
|
WO2025160324A2
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250263471A1
(en)
|
2024-01-30 |
2025-08-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating allergy using anti-bet v 1 antibodies
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
US20250255282A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025171411A1
(en)
|
2024-02-09 |
2025-08-14 |
Herophilus, Inc. |
Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
|
|
WO2025179282A1
(en)
|
2024-02-23 |
2025-08-28 |
Flatiron Bio, Llc |
Antibodies targeting epstein-barr virus proteins and methods of use
|
|
WO2025194126A1
(en)
|
2024-03-15 |
2025-09-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency
|
|
US20250295801A1
(en)
|
2024-03-21 |
2025-09-25 |
Seagen Inc. |
Cd25 antibodies, antibody drug conjugates, and uses thereof
|
|
WO2025202147A1
(en)
|
2024-03-27 |
2025-10-02 |
F. Hoffmann-La Roche Ag |
Interleukin-7 immunoconjugates
|
|
WO2025221640A1
(en)
|
2024-04-15 |
2025-10-23 |
Sanofi Biotechnology |
Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
|
|
WO2025226808A1
(en)
|
2024-04-24 |
2025-10-30 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
|
WO2025224297A1
(en)
|
2024-04-26 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to tgfbi and uses thereof
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|
|
WO2025259871A1
(en)
|
2024-06-14 |
2025-12-18 |
Gilead Sciences, Inc. |
Anti-ccr8 antibodies and uses thereof
|